Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Breast Cancer Res
    September 2026
  1. ISHIGURO H, Miyoshi Y, Yasojima H, Watanabe J, et al
    E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.
    Breast Cancer Res. 2026;28:158.
    >> Share

  2. SARAFIDIS M, Sifakis EG, Bergh J, Foukakis T, et al
    Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer.
    Breast Cancer Res. 2026;28:156.
    >> Share

  3. SHEPHERD J, Bertrand K, Strand F, Vachon C, et al
    International breast density and cancer risk assessment workshop: advances, challenges, and emerging solutions, a summary from the 11th IBDW, Kaua'i 2025.
    Breast Cancer Res. 2026;28.
    >> Share

    August 2026
  4. BADAWY W
    Computational methods, clinical evidence, and translational readiness for artificial intelligence for HER2 assessment using silver in situ hybridization (SISH).
    Breast Cancer Res. 2026;28:146.
    >> Share

  5. ADDISSIE YA, Greer YE, Nair J, Lipkowitz S, et al
    Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer.
    Breast Cancer Res. 2026;28:144.
    >> Share

  6. ACS B, Liu X, Gkekos L, Karlsson E, et al
    Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.
    Breast Cancer Res. 2026;28:139.
    >> Share

  7. MU J, Zhang M, Chen Q, Liu W, et al
    Unveiling CCL5: the master regulator of breast cancer progression and immune evasion.
    Breast Cancer Res. 2026;28:159.
    >> Share

    July 2026
  8. DING Y, Yu J, Liu M, Liu X, et al
    Enhancing lymph node metastases assessment in breast cancer post-neoadjuvant therapy using artificial intelligence-driven diagnostics.
    Breast Cancer Res. 2026 Jul 21. doi: 10.1186/s13058-026-02349.
    >> Share

  9. ALEIXO G, Hwang WT, Sharma R, Jung W, et al
    The association between adiposity and cardiac function in patients with early breast cancer receiving cardiotoxic therapies.
    Breast Cancer Res. 2026 Jul 21. doi: 10.1186/s13058-026-02350.
    >> Share

  10. HOLM KY, Mohammed Y, Gunnarsdottir Thormar V, Eiriksson FF, et al
    Diagnostic plasma protein signatures in sporadic and BRCA1/2 breast cancer patients via targeted proteomics.
    Breast Cancer Res. 2026 Jul 18. doi: 10.1186/s13058-026-02348.
    >> Share

  11. LU H, Bagheri M, Kolling FW, Salas LA, et al
    Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer.
    Breast Cancer Res. 2026;28:132.
    >> Share

  12. COSENTINO G, Lecchi M, Giussani M, Fogazzi V, et al
    Three ct-miRNA signature predicts disease outcome in early breast cancer women.
    Breast Cancer Res. 2026 Jul 15. doi: 10.1186/s13058-026-02344.
    >> Share

  13. CAO A, Fuller S, Zanudo JGT, Chen WY, et al
    Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.
    Breast Cancer Res. 2026 Jul 10. doi: 10.1186/s13058-026-02337.
    >> Share

  14. LONG J, Liu B, Li J, Wang X, et al
    Development and validation of an immune-related molecular subtyping model based on a four-gene prognostic biomarker signature and multi-omics integrative analysis in Luminal B breast cancer.
    Breast Cancer Res. 2026 Jul 10. doi: 10.1186/s13058-026-02342.
    >> Share

  15. YAN C, Cui F, Liu C, Ling R, et al
    LMAN2 promotes breast cancer progression and deduces cell sensitivity to doxorubicin through stearoyl-CoA desaturase.
    Breast Cancer Res. 2026 Jul 8. doi: 10.1186/s13058-026-02343.
    >> Share

  16. NIMBALKAR VP, V P S, Dash A, Jothikumar M, et al
    Postpartum breast cancer as a distinct oncologic entity: linking physiological tissue remodelling to tumor biology and clinical translation.
    Breast Cancer Res. 2026 Jul 8. doi: 10.1186/s13058-026-02341.
    >> Share

  17. SARTORI GP, Ramalho S, da Silva LR, Telles GD, et al
    H-score and ERBB2 mRNA refine identification of HER2-low and HER2-ultralow breast cancer.
    Breast Cancer Res. 2026 Jul 8. doi: 10.1186/s13058-026-02334.
    >> Share

  18. WANG R, Li X, Zhu H, Li L, et al
    Predicting sentinel lymph node metastasis in breast cancer using an interpretable machine learning approach based on multi-domain clinical features.
    Breast Cancer Res. 2026 Jul 7. doi: 10.1186/s13058-026-02329.
    >> Share

  19. FIORIN A, Adalid-Llansa L, Reverte L, Sauras-Colon E, et al
    Longitudinal evaluation of tumor-infiltrating lymphocyte scoring using automated region of interest registration in breast cancer.
    Breast Cancer Res. 2026 Jul 3. doi: 10.1186/s13058-026-02333.
    >> Share

    June 2026
  20. WANG X, Ni Y, Shi Y, Yu X, et al
    Exploring LTB-mediated T cell differentiation as a prognostic marker in triple-negative breast cancer.
    Breast Cancer Res. 2026 Jun 30. doi: 10.1186/s13058-026-02332.
    >> Share

  21. ZHANG Y, Li K, Zhang S, Yang H, et al
    Intraoperative NIR-II fluorescence guidance for precise tumor margin assessment and maximized tissue preservation in breast surgery.
    Breast Cancer Res. 2026;28:154.
    >> Share

  22. ZAREAN E, Li S, Makalic E, Milne RL, et al
    Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases.
    Breast Cancer Res. 2026 Jun 26. doi: 10.1186/s13058-026-02327.
    >> Share

  23. NACER DF, Veerla S, Sasiain I, Hakkinen J, et al
    Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer.
    Breast Cancer Res. 2026;28:115.
    >> Share

  24. WANG J, Yao L, Chen Y, Zhu Q, et al
    FBXO5 regulates RPL23A to promote MDM2-mediated p53 degradation and facilitate malignant progression of breast cancer.
    Breast Cancer Res. 2026 Jun 25. doi: 10.1186/s13058-026-02335.
    >> Share

  25. TELANG S, Clem BF, Miret AAH, Price L, et al
    Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer.
    Breast Cancer Res. 2026 Jun 25. doi: 10.1186/s13058-026-02336.
    >> Share

  26. PENA-ENRIQUEZ R, Guerrero-Zotano A, Bermejo B, Diaz-Chacon A, et al
    Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.
    Breast Cancer Res. 2026 Jun 24. doi: 10.1186/s13058-026-02330.
    >> Share

  27. STABELLINI N, de Oliveira SD, Mizukami T, Sweeney SM, et al
    Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.
    Breast Cancer Res. 2026 Jun 20. doi: 10.1186/s13058-026-02324.
    >> Share

  28. GORDON B, Swaminathan B, Youn SW, Obacz NA, et al
    Tumor cell Jagged-1 promotes regional lymphatic metastasis and predicts recurrence in node-positive breast cancer.
    Breast Cancer Res. 2026 Jun 19. doi: 10.1186/s13058-026-02331.
    >> Share

  29. GUZ J, Urbanowska-Domanska O, Zarakowska E, Gackowski D, et al
    Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer.
    Breast Cancer Res. 2026 Jun 18. doi: 10.1186/s13058-026-02314.
    >> Share

  30. NICOLA C, Peter E, Villagran-Garcia M, Treilleux I, et al
    Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.
    Breast Cancer Res. 2026;28:148.
    >> Share

  31. NAKAO K, Komura M, Inaguma S, Nagano A, et al
    Highly CD81-expressing stromal cells characterize a tumor-suppressive immune microenvironment in invasive breast cancer.
    Breast Cancer Res. 2026 Jun 14. doi: 10.1186/s13058-026-02326.
    >> Share

  32. VIGNOT S, Drouet Y, Di Meglio A, Martin AL, et al
    Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.
    Breast Cancer Res. 2026 Jun 9. doi: 10.1186/s13058-026-02315.
    >> Share

  33. YANG Y, Lin Y
    Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside.
    Breast Cancer Res. 2026 Jun 9. doi: 10.1186/s13058-026-02320.
    >> Share

  34. BARNARD ME, Xu NN, Holder EX, Jones D, et al
    Hypertension, use of antihypertensive medications and breast cancer survival among Black women.
    Breast Cancer Res. 2026 Jun 6. doi: 10.1186/s13058-026-02317.
    >> Share

  35. CHEN WL, Liu WL, Guo CP, Zhu YY, et al
    Intraoperative measurement of breast-conserving surgery margins: surgical application.
    Breast Cancer Res. 2026;28:141.
    >> Share

  36. MONTOYO-PUJOL YG, Martinez-Peinado P, Pascual-Garcia S, Ortuno-Miquel S, et al
    A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.
    Breast Cancer Res. 2026 Jun 4. doi: 10.1186/s13058-026-02319.
    >> Share

    May 2026
  37. ISHIKAWA T, Uemura Y, Seki H, Kitada M, et al
    Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.
    Breast Cancer Res. 2026 May 29. doi: 10.1186/s13058-026-02313.
    >> Share

  38. BUYUKKUSCU A, Isleyen ZS, Ekinci OB, Atasever T, et al
    Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study.
    Breast Cancer Res. 2026 May 28. doi: 10.1186/s13058-026-02312.
    >> Share

  39. ALI FAIRBAIRN S, Kim K, Cowan RW, Lessey LR, et al
    Kaiso modulates androgen receptor expression in triple-negative breast cancer.
    Breast Cancer Res. 2026 May 28. doi: 10.1186/s13058-026-02299.
    >> Share

  40. VETA DARKOVSKI J, Michelon I, Gazzoni G, Mamede I, et al
    CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data.
    Breast Cancer Res. 2026;28:100.
    >> Share

  41. SERVITJA S, Carrasco E, Andres R, Rodriguez-Lescure A, et al
    Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.
    Breast Cancer Res. 2026 May 25. doi: 10.1186/s13058-026-02300.
    >> Share

  42. LIU Q, Fan J, Peng W, Deng S, et al
    ZNF831 suppresses triple-negative breast cancer progression through NLRP3-associated pyroptotic signaling and M1-like macrophage phenotypic remodeling.
    Breast Cancer Res. 2026 May 23. doi: 10.1186/s13058-026-02307.
    >> Share

  43. OSHI M, Sugimori M, Kawashima K, Gandhi S, et al
    TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.
    Breast Cancer Res. 2026 May 22. doi: 10.1186/s13058-026-02305.
    >> Share

  44. WOO H, Han S, Heo J, Cho J, et al
    Germline APOE epsilon2 homozygosity and reduced risk of breast cancer: a population-based cohort study.
    Breast Cancer Res. 2026 May 22. doi: 10.1186/s13058-026-02308.
    >> Share

  45. HUANG X, Li T, Ye S, Lan Y, et al
    Tamoxifen-pretreated MSC exosomes promote endocrine resistance in ER-positive breast cancer cells through the miR-137/Serpina3 axis: a mechanistic study.
    Breast Cancer Res. 2026 May 21. doi: 10.1186/s13058-026-02306.
    >> Share

  46. DE NEGREIROS BOTAN R, de Sousa JB
    Corepam: a 24-gene PAM50-derived expression score with cross-platform external validation for breast cancer prognosis.
    Breast Cancer Res. 2026 May 21. doi: 10.1186/s13058-026-02298.
    >> Share

  47. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea Baz N, Pachon-Olmos V, et al
    Adherence to the WCRF/AICR cancer prevention recommendations and mammographic density.
    Breast Cancer Res. 2026;28:131.
    >> Share

  48. SANVIDO VM, Bromberg SE, Waitzberg AFL, Gomes JO, et al
    Cryoablation for early-stage invasive breast cancer: pathologic and imaging outcomes from the prospective FIRST trial.
    Breast Cancer Res. 2026 May 19. doi: 10.1186/s13058-026-02302.
    >> Share

  49. YE S, Jin Z, Li W, Wei G, et al
    Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives.
    Breast Cancer Res. 2026 May 18. doi: 10.1186/s13058-026-02303.
    >> Share

  50. YU W, Jiang L
    CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation.
    Breast Cancer Res. 2026 May 15. doi: 10.1186/s13058-026-02288.
    >> Share

  51. CHENG C, Yuan F, Li J, Fan Y, et al
    High-fat diet reshapes microbial interactions to promote breast cancer stemness via Streptococcus mutans-induced leucine accumulation.
    Breast Cancer Res. 2026 May 11. doi: 10.1186/s13058-026-02297.
    >> Share

  52. MARTINEZ-ILLESCAS NG, Martin-Zapater E, Quezada-Gutierrez C, Yebenes L, et al
    Tumor ecology and the paradox of clean margins in multicentric breast cancer: an exploratory organoid-based functional study.
    Breast Cancer Res. 2026 May 9. doi: 10.1186/s13058-026-02301.
    >> Share

  53. FISCHER-CARLES A, Fiorin A, Lopez Pablo C, Reverte L, et al
    Leveraging immune and clinicopathological profiles with machine learning to predict axillary lymph node metastasis in breast cancer patients.
    Breast Cancer Res. 2026 May 8. doi: 10.1186/s13058-026-02294.
    >> Share

  54. SAUNDERS AAE, Mouchemore KA, Vojtech L, James LS, et al
    Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling.
    Breast Cancer Res. 2026 May 7. doi: 10.1186/s13058-026-02296.
    >> Share

  55. SUN L, Wang Z, Zhang W, Yang Y, et al
    Multimodal radiomics incorporating intratumoral heterogeneity for prognostic assessment of metastatic outcomes in invasive breast cancer.
    Breast Cancer Res. 2026 May 7. doi: 10.1186/s13058-026-02287.
    >> Share

  56. SETH S, Yam C, Huo L, Lim B, et al
    The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Breast Cancer Res. 2026 May 6. doi: 10.1186/s13058-026-02290.
    >> Share

  57. HAZRA A, Berdan E, Walsh T, Humble S, et al
    Transcriptome predictors of second breast events in ductal carcinoma in situ: a case?control study including Black and White women.
    Breast Cancer Res. 2026;28:86.
    >> Share

  58. DE OLIVEIRA ANDRADE F, Staley C, Jin L, Ozgul-Onal M, et al
    Gut microbiome modulates breast cancer risk in socially isolated mice.
    Breast Cancer Res. 2026 May 2. doi: 10.1186/s13058-026-02292.
    >> Share

  59. CRUZ-REYES N, Liang H, Stallings-Mann M, Pacheco-Spann L, et al
    Multi?scale immune and spatial profiling of sclerosing adenosis and surrounding breast tissue identifies an immune?cold field phenotype associated with breast cancer risk.
    Breast Cancer Res. 2026 May 2. doi: 10.1186/s13058-026-02293.
    >> Share

    April 2026
  60. GHANTA P, Verma AK, Lin CH, Charan M, et al
    Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression.
    Breast Cancer Res. 2026;28:112.
    >> Share

  61. HARA M, Hachiya T, Furukawa T, Nishida Y, et al
    Predictive performance of breast cancer polygenic risk scores from diverse ancestries: a prospective study in Japanese women.
    Breast Cancer Res. 2026 Apr 28. doi: 10.1186/s13058-026-02256.
    >> Share

  62. LI Y, Li Z, Dai J
    Tumor-infiltrating lymphocytes in triple-negative breast cancer: molecular mechanisms, spatial regulation, and therapeutic implications.
    Breast Cancer Res. 2026 Apr 26. doi: 10.1186/s13058-026-02285.
    >> Share

  63. SASAKI A, Hosonuma M, Maruyama Y, Funayama E, et al
    Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial-mesenchymal transition via histamine H(1) receptor inverse agonism.
    Breast Cancer Res. 2026;28:113.
    >> Share

  64. LI T, Lian B, Liu Y, Guo L, et al
    Identification and validation of an intratumor heterogeneity-related prognostic signature in triple-negative breast cancer: a study based on integrative machine learning and single-cell sequence.
    Breast Cancer Res. 2026 Apr 25. doi: 10.1186/s13058-026-02291.
    >> Share

  65. SONG PN, DeMellier CT, Lynch SE, Gallegos CA, et al
    CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer.
    Breast Cancer Res. 2026 Apr 25. doi: 10.1186/s13058-026-02286.
    >> Share

  66. LIGHTOWLERS SV, Roman-Escorza M, Welsh C, Bliss JM, et al
    Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials.
    Breast Cancer Res. 2026;28:108.
    >> Share

  67. ZHOU L, Ruan M, Wu J, Wu Q, et al
    The absence of B7-H4 inhibits PD-L1 expression by driving a methylation of PD-L1 promoter in breast cancer cells.
    Breast Cancer Res. 2026 Apr 22. doi: 10.1186/s13058-026-02289.
    >> Share

  68. FAN Y, Zhao Y, Zhang H, Ma T, et al
    Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.
    Breast Cancer Res. 2026 Apr 19. doi: 10.1186/s13058-026-02278.
    >> Share

  69. SMITH SJ, Gibson C, Moorin R, Newton J, et al
    "Hurtled down a track and then thrown off": experiences of longitudinal breast cancer care trajectories of women living with and beyond breast cancer.
    Breast Cancer Res. 2026 Apr 18. doi: 10.1186/s13058-026-02264.
    >> Share

  70. LONNING PE, Nikolaienko O, Knappskog S
    Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.
    Breast Cancer Res. 2026 Apr 17. doi: 10.1186/s13058-026-02279.
    >> Share

  71. ZHAO X, Fan Y, Yang J, Gao H, et al
    Single-cell transcriptomics identify mechanical-memory-associated cell states in metastatic HR(+) breast cancer.
    Breast Cancer Res. 2026 Apr 17. doi: 10.1186/s13058-026-02280.
    >> Share

  72. BI C, Li Q, Deng L, Ren Z, et al
    Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features.
    Breast Cancer Res. 2026;28:102.
    >> Share

  73. LIU L, Gao Y, Yu D, Li D, et al
    TFRC promotes ferroptosis to suppress breast cancer bone metastasis via the activation of HIF-1 pathway.
    Breast Cancer Res. 2026 Apr 15. doi: 10.1186/s13058-026-02269.
    >> Share

  74. KLAUS FL, Kitzke I, Klein E, Mogler C, et al
    MUCL1 in triple-negative breast cancer: a novel marker associated with the luminal androgen receptor subtype.
    Breast Cancer Res. 2026;28:73.
    >> Share

  75. YOSHIDA T, Wei F, Kouro T, Kawaguchi K, et al
    Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
    Breast Cancer Res. 2026 Apr 15. doi: 10.1186/s13058-026-02259.
    >> Share

  76. ZOPF EM, Joernaker G, Clauss D, Trevaskis M, et al
    Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study.
    Breast Cancer Res. 2026 Apr 13. doi: 10.1186/s13058-026-02235.
    >> Share

  77. GAO T, Li K, Lei H, Wang J, et al
    Advantages of nitroglycerin application in preoperative CTA for DIEP flap breast reconstruction.
    Breast Cancer Res. 2026;28:95.
    >> Share

  78. SWITALLA KM, Onishi N, Jones EF, Lawhn-Heath C, et al
    A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Breast Cancer Res. 2026;28:93.
    >> Share

  79. ZIRPOLI G, Pfeiffer RM, Palmer JR
    Performance of three breast cancer risk assessment tools in US Black women.
    Breast Cancer Res. 2026 Apr 9. doi: 10.1186/s13058-026-02274.
    >> Share

  80. SHIN SH, Ahn SG, Ryu JM, Lee SB, et al
    Contributing factors of contralateral breast cancer in patients with BRCA mutation (ON-BRCA II study, KoREa-BSG 11).
    Breast Cancer Res. 2026 Apr 9. doi: 10.1186/s13058-026-02273.
    >> Share

  81. SILVESTRI V, Valentini V, Bucalo A, Porzio V, et al
    Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.
    Breast Cancer Res. 2026 Apr 7. doi: 10.1186/s13058-026-02236.
    >> Share

  82. DU L, Zhu L, Yang Y, Pan L, et al
    TTPAL inhibits the progression of breast cancer and reprograms tumor-associated macrophages by inhibiting JAK2/STAT3 signaling pathway.
    Breast Cancer Res. 2026 Apr 5. doi: 10.1186/s13058-026-02246.
    >> Share

  83. LI Z, Su H, Xiao H, Chen C, et al
    Integrating tumor habitat heterogeneity with a hybrid deep learning architecture for ultrasound radiomics: a dual-center study on non-invasive prediction of PD-L1 expression in triple-negative breast cancer.
    Breast Cancer Res. 2026 Apr 4. doi: 10.1186/s13058-026-02275.
    >> Share

  84. MELLOR P, Smith SE, Kendall S, Kyrylenko L, et al
    CLIC3 is upregulated across all subtypes of breast cancer and plays a key role in cell migration, invasion and growth in soft agar.
    Breast Cancer Res. 2026 Apr 3. doi: 10.1186/s13058-026-02270.
    >> Share

  85. ABE JV, Fukui J, Wilkens LR, Cheng I, et al
    Risk factors for ductal carcinoma in situ: comparisons with invasive breast cancer.
    Breast Cancer Res. 2026 Apr 1. doi: 10.1186/s13058-026-02266.
    >> Share

    March 2026
  86. DENG R, Ren Y, Hu K, Zhang Y, et al
    Integrated multi-omics analysis and functional validation reveal the role of TRIM2 as a potential novel biomarker in breast cancer.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02263.
    >> Share

  87. TANG L
    Single-cell landscape of intratumoral heterogeneity and GABA-mediated remodeling of the immune microenvironment in breast cancer metastases.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02268.
    >> Share

  88. LUNDGREN C, Frediksson I, Valachis A, Smith DR, et al
    PREDICT v3.0 outperforms v2.2 in young (25-40 years) breast cancer patients according to real-world data from a large Swedish population-based registry.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02271.
    >> Share

  89. GAO Y, Xu M, Zhang M, Sun G, et al
    Development and validation of an online prognostic risk stratification tool to assist decisions on perioperative chemotherapy for men with luminal early breast cancer.
    Breast Cancer Res. 2026 Mar 28. doi: 10.1186/s13058-026-02252.
    >> Share

  90. CHEN L, Kong L, Yang J, Xue J, et al
    [(68)Ga]Ga-labeled fibroblast activation protein inhibitor PET/CT for monitoring neoadjuvant chemotherapy responses in breast cancer subtypes.
    Breast Cancer Res. 2026 Mar 28. doi: 10.1186/s13058-026-02267.
    >> Share

  91. ALI S, Bains S, Fox E, Desai A, et al
    Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.
    Breast Cancer Res. 2026;28:83.
    >> Share

  92. ANNIBALINI G, Sisti D, De Santi M, Natalucci V, et al
    Lifestyle intervention based on aerobic exercise and Mediterranean diet modulates IGF-1 and its binding proteins in breast cancer survivors.
    Breast Cancer Res. 2026 Mar 27. doi: 10.1186/s13058-026-02262.
    >> Share

  93. LIU S, Liu A, Zhang L, Li J, et al
    CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer.
    Breast Cancer Res. 2026 Mar 22. doi: 10.1186/s13058-026-02248.
    >> Share

  94. WANG Z, Chen X, Han X, Cao X, et al
    Deubiquitination and stabilization of EIF4A3 by OTUB2 contributes to TPI1-mediated glycolysis and TNBC progression.
    Breast Cancer Res. 2026;28:77.
    >> Share

  95. MOSHINA N, Gjesvik J, Castells X, Larsen M, et al
    Breast cancer mortality among women who have attended BreastScreen Norway, 1996-2023.
    Breast Cancer Res. 2026 Mar 17. doi: 10.1186/s13058-026-02244.
    >> Share

  96. WANG XP, Han Y, Yao M, Gao HW, et al
    AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening.
    Breast Cancer Res. 2026;28:76.
    >> Share

  97. WANG R, Liu S, Zhao Y, Su Y, et al
    TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtypes.
    Breast Cancer Res. 2026 Mar 16. doi: 10.1186/s13058-026-02241.
    >> Share

  98. ZHOU Q, Zhu Z, Zhao Y, Jing D, et al
    CD19(+)Ki67(+)B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasis.
    Breast Cancer Res. 2026 Mar 9. doi: 10.1186/s13058-026-02251.
    >> Share

  99. ZOU L, Tang X, Deng P, Liu Y, et al
    Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study.
    Breast Cancer Res. 2026 Mar 4. doi: 10.1186/s13058-026-02254.
    >> Share

  100. PHOENIX KN, Singh V, Murphy PA, Claffey KP, et al
    Transcriptomic profiles from normal and tumor tissue samples reveal distinct venule populations and novel tumor endothelial cell markers in breast cancer.
    Breast Cancer Res. 2026 Mar 3. doi: 10.1186/s13058-026-02249.
    >> Share

  101. LI Y, Wang W, Liang Y, Lai H, et al
    Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer.
    Breast Cancer Res. 2026 Mar 3. doi: 10.1186/s13058-026-02255.
    >> Share

    February 2026
  102. CHEN J, Ma L, Yin M, Sun J, et al
    FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug delivery.
    Breast Cancer Res. 2026 Feb 26. doi: 10.1186/s13058-026-02247.
    >> Share

  103. DE GRUIL N, de Groot AF, Wesseling-Rozendaal Y, Keizer D, et al
    Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.
    Breast Cancer Res. 2026 Feb 25. doi: 10.1186/s13058-026-02245.
    >> Share

  104. JITWATCHARAKOMOL T, Gokun Y, Daniel SJ, Mestres-Villanueva M, et al
    Outcomes of once daily and twice daily accelerated partial breast irradiation regimens in hormone receptor positive breast cancer: a single institution experience.
    Breast Cancer Res. 2026 Feb 23. doi: 10.1186/s13058-026-02243.
    >> Share

  105. ZHANG N, Zhang J, Shao J, Huang Z, et al
    Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer.
    Breast Cancer Res. 2026 Feb 21. doi: 10.1186/s13058-026-02240.
    >> Share

  106. ZHOU Y, Guo C, Wang Y, Xu H, et al
    Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.
    Breast Cancer Res. 2026;28:64.
    >> Share

  107. DEHGHAN MANSHADI M, Hashemi F, Safaei S, Golshahi H, et al
    Prophylactic and therapeutic CSC-based vaccination reduced tumor growth, metastasis and enhanced survival in mouse model of breast cancer.
    Breast Cancer Res. 2026 Feb 19. doi: 10.1186/s13058-026-02242.
    >> Share

  108. SAVARIDAS SL, Marshall A, Ali K, Astley SM, et al
    Change in mammographic density as a potential predictor of cancer recurrence after breast conservation surgery and adjuvant endocrine therapy: results of the MEDICI study.
    Breast Cancer Res. 2026;28:62.
    >> Share

  109. BREMER T, Mittal K, Shah C, Vicini F, et al
    Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.
    Breast Cancer Res. 2026 Feb 18. doi: 10.1186/s13058-026-02237.
    >> Share

  110. ALDRICH MB, McWain ME, Shaitelman SF, Kuhns RE, et al
    Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.
    Breast Cancer Res. 2026 Feb 17. doi: 10.1186/s13058-026-02231.
    >> Share

  111. ELAHI SF, Martin DP, Wan Y, Zhang L, et al
    4-Hydroxybutyrate (4HB) released from poly-4-hydroxybutyrate scaffolds does not impact hallmark phenotypes of cancer in malignant or non-malignant breast cells.
    Breast Cancer Res. 2026;28:60.
    >> Share

  112. MAO X, Cao X, Qian L, Gao M, et al
    Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors.
    Breast Cancer Res. 2026;28:59.
    >> Share

  113. ZHAI Z, Wu J, Wei Y, Song P, et al
    O-GlcNAcylation regulates the DNA damage repair function of MND1 in breast cancer.
    Breast Cancer Res. 2026 Feb 10. doi: 10.1186/s13058-026-02233.
    >> Share

  114. TENG X, Zhang J, Lai Q, Li W, et al
    Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 trial.
    Breast Cancer Res. 2026;28:39.
    >> Share

  115. BURKE A, Fan S, Pfeiffer RM, Bodelon C, et al
    Associations of local breast density with patient characteristics and risk of breast cancer among women undergoing diagnostic breast biopsy.
    Breast Cancer Res. 2026 Feb 4. doi: 10.1186/s13058-025-02212.
    >> Share

  116. YANG L, Toriola AT
    Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.
    Breast Cancer Res. 2026 Feb 3. doi: 10.1186/s13058-026-02222.
    >> Share

    January 2026
  117. SHEN S, Teysir J, Safonov A, Bromberg M, et al
    Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res. 2026 Jan 31. doi: 10.1186/s13058-025-02152.
    >> Share

  118. BOOMSTRA E, de Ligt KM, Tissier R, Clouth F, et al
    One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer.
    Breast Cancer Res. 2026 Jan 30. doi: 10.1186/s13058-026-02228.
    >> Share

  119. HLADIK C, Elayapillai SP, Dogra S, Bruns M, et al
    Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ.
    Breast Cancer Res. 2026;28:52.
    >> Share

  120. YANG L, Chen Z, Chen Y, Yang J, et al
    Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer.
    Breast Cancer Res. 2026 Jan 29. doi: 10.1186/s13058-026-02230.
    >> Share

  121. XU FF, Zheng SF, Shao ZY, Qi WX, et al
    The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy.
    Breast Cancer Res. 2026;28:50.
    >> Share

  122. YU CC, Hsieh CC, Huang YT, Chu CH, et al
    Toxicity profiles of proton and photon radiotherapy in postoperative breast cancer: a 10-year real-world cohort study.
    Breast Cancer Res. 2026 Jan 27. doi: 10.1186/s13058-026-02227.
    >> Share

  123. FANG Y, Guo C, Zheng F, Xiao Y, et al
    HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling.
    Breast Cancer Res. 2026 Jan 27. doi: 10.1186/s13058-026-02225.
    >> Share

  124. COHEN EN, Gao H, Tin S, Wu Q, et al
    High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses.
    Breast Cancer Res. 2026;28:3.
    >> Share

  125. RAJAN KK, Nijveldt JJ, Helthuis JHG, Roeloffzen EMA, et al
    Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients.
    Breast Cancer Res. 2026 Jan 23. doi: 10.1186/s13058-026-02223.
    >> Share

  126. LEI L, Bhave M, Kalinsky K, Gandhi S, et al
    Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.
    Breast Cancer Res. 2026 Jan 22. doi: 10.1186/s13058-025-02203.
    >> Share

  127. HE X, Tong W, Chen X, Huang H, et al
    TRPS1 confers paclitaxel resistance in TNBC through dual activation of the PDE4D-cAMP-AKT pathway and microtubule destabilization.
    Breast Cancer Res. 2026;28:47.
    >> Share

  128. BASU GD, Innis PE, Deem AK, Starodynov A, et al
    Characterization of ESR1 alterations in patients with breast and gynecologic cancers.
    Breast Cancer Res. 2026;28:40.
    >> Share

  129. TIKUM AF, Fon DA, Njotu FN, Henning N, et al
    [(225)Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.
    Breast Cancer Res. 2026 Jan 16. doi: 10.1186/s13058-026-02220.
    >> Share

  130. TROISI R, Falk RT, Surcel HM, Kauppila S, et al
    Estrogen metabolism pathways in pregnancy and subsequent breast cancer risk: a prospective follow-up study.
    Breast Cancer Res. 2026 Jan 16. doi: 10.1186/s13058-025-02204.
    >> Share

  131. YAN Y, Narayan A, Mazinani M, Saeki H, et al
    CRYbetaB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer.
    Breast Cancer Res. 2026 Jan 14. doi: 10.1186/s13058-025-02188.
    >> Share

  132. RONY R, Deng S, Yang S, Doig K, et al
    Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases.
    Breast Cancer Res. 2026;28:5.
    >> Share

  133. MOSQUIM JUNIOR S, Zamore M, Vallon-Christersson J, Ryden L, et al
    Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread.
    Breast Cancer Res. 2026;28:12.
    >> Share

  134. PANTALEO J, Sjolund J, Bolivar P, Bocci M, et al
    Spatial and temporal dynamics of cancer-associated fibroblast niches in breast cancer.
    Breast Cancer Res. 2026 Jan 11. doi: 10.1186/s13058-025-02183.
    >> Share

  135. EKSTROM K, Riaz N, Larsson K, Nemeth A, et al
    Plasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment.
    Breast Cancer Res. 2026 Jan 9. doi: 10.1186/s13058-025-02209.
    >> Share

  136. MARCHAL MI, Mutie PM, Azimi T, Deng YA, et al
    Distinct genetic profiles of obesity have different effects on breast cancer risk: leveraging Mendelian randomisation to interrogate causal pathways and identify mediating proteins.
    Breast Cancer Res. 2026 Jan 9. doi: 10.1186/s13058-025-02214.
    >> Share

  137. LEE JA, Lee HS, Jeon S, Kim D, et al
    Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: a nationwide population-based cohort study.
    Breast Cancer Res. 2026 Jan 7. doi: 10.1186/s13058-025-02211.
    >> Share

  138. KEHM RD, Lilge L, Walter EJ, Santella RM, et al
    Recreational physical activity and biomarkers of breast cancer risk in a cohort of adolescent girls.
    Breast Cancer Res. 2026 Jan 7. doi: 10.1186/s13058-025-02216.
    >> Share

  139. SHAW R, Cornwall D, Badal S, Powell LP, et al
    Molecular subtypes of breast cancer in Jamaican women: high prevalence of triple-negative and HER2 + disease.
    Breast Cancer Res. 2026 Jan 6. doi: 10.1186/s13058-025-02175.
    >> Share

  140. YAN P, Wu F, Afanasyeva Y, Arslan A, et al
    Premenopausal serum midkine levels and risk of estrogen receptor positive breast cancer: a prospective, nested case-control study.
    Breast Cancer Res. 2026 Jan 6. doi: 10.1186/s13058-025-02210.
    >> Share

  141. VAN BERCKELAER C, Van Laere S, Vermeulen C, Kockx M, et al
    The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.
    Breast Cancer Res. 2026 Jan 5. doi: 10.1186/s13058-025-02192.
    >> Share

  142. PANAGOPOULOU M, Papadaki MA, Karaglani M, Theodosiou T, et al
    Nuovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.
    Breast Cancer Res. 2026;28:1.
    >> Share

  143. LIM GY, Ka NL, Kim SS, Lee MO, et al
    IFI16/IFI202 blockade suppresses tumor growth through CD8(+) T-cell-mediated immunity.
    Breast Cancer Res. 2026;28:27.
    >> Share

  144. JIANG L, Xu J, Jiang C, Jia Y, et al
    BHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1.
    Breast Cancer Res. 2026 Jan 2. doi: 10.1186/s13058-025-02198.
    >> Share

    December 2025
  145. ZHU Q, Bennett D, Hagemann IS, Mannix J, et al
    Ultrasound-guided diffuse optical tomography: an adjunct to ultrasound that can reduce unnecessary breast biopsies.
    Breast Cancer Res. 2025;28:31.
    >> Share

  146. COLLIN LJ, Woolpert KM, Kjaersgaard A, Ahern TP, et al
    17beta-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.
    Breast Cancer Res. 2025 Dec 30. doi: 10.1186/s13058-025-02196.
    >> Share

  147. YU HH, Gracia D, Chao TC, Ho CH, et al
    Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity.
    Breast Cancer Res. 2025;27:222.
    >> Share

  148. ELKUM N, Al-Zahrani AS, Alraouji NN, Al-Tweigeri T, et al
    Obesity is a major modifiable factor associated with ER-negative breast cancer: epidemiological and mechanistic evidence from a high-risk cohort.
    Breast Cancer Res. 2025 Dec 29. doi: 10.1186/s13058-025-02189.
    >> Share

  149. TSENG LM, Huang CC, Chen JL, Tsai YF, et al
    Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR study.
    Breast Cancer Res. 2025;27:221.
    >> Share

  150. KHAN Y, Verhaeghe N, Monten C, Vanthomme K, et al
    Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis.
    Breast Cancer Res. 2025 Dec 28. doi: 10.1186/s13058-025-02207.
    >> Share

  151. REEVES G, Pirie K, Floud S, Black J, et al
    The aetiology of breast cancer subtypes: results from the Million Women Study.
    Breast Cancer Res. 2025 Dec 28. doi: 10.1186/s13058-025-02197.
    >> Share

  152. BORGEL A, Camenen E, Miquel C, Bertheau P, et al
    Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors.
    Breast Cancer Res. 2025;28:26.
    >> Share

  153. PANG J, Chen Y, Wang H, Tang Y, et al
    Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer.
    Breast Cancer Res. 2025 Dec 26. doi: 10.1186/s13058-025-02182.
    >> Share

  154. DAHMS PA, Hinckley B, Prekeris R, Behbod F, et al
    Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion.
    Breast Cancer Res. 2025;28:25.
    >> Share

  155. GRAM IT, Park SY, Wilkens LR, Haiman CA, et al
    Childhood exposure to second-hand smoke (SHS) and risk of breast cancer in postmenopausal never smokers: the Multiethnic Cohort (MEC) study.
    Breast Cancer Res. 2025 Dec 25. doi: 10.1186/s13058-025-02202.
    >> Share

  156. GU J, Qi Q, Mao X, Cong R, et al
    Integrated transcriptome study reveals a stress response state CD4 +T cells related to immune tolerance in breast cancer.
    Breast Cancer Res. 2025 Dec 24. doi: 10.1186/s13058-025-02205.
    >> Share

  157. MOIR N, Pearce DA, Langdon SP, Simpson TI, et al
    The significance of molecular heterogeneity in breast cancer batch correction and dataset integration.
    Breast Cancer Res. 2025;27:219.
    >> Share

  158. DUTHEIL J, Pereira V, Boisson C, Mansi L, et al
    Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.
    Breast Cancer Res. 2025;27:220.
    >> Share

  159. CASTRESANA-AGUIRRE M, Matikas A, Lindstrom LS, Tobin NP, et al
    Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes.
    Breast Cancer Res. 2025 Dec 24. doi: 10.1186/s13058-025-02208.
    >> Share

  160. FORMISANO L, Nappi L, Rosa R, Marciano R, et al
    Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Breast Cancer Res. 2025;27:218.
    >> Share

  161. GUO L, Li J, Zhu W, Wang Z, et al
    PAK2 promotes CTC cluster formation by phosphorylating E-cadherin to enhance cell-cell adhesion in breast cancer.
    Breast Cancer Res. 2025 Dec 21. doi: 10.1186/s13058-025-02199.
    >> Share

  162. BHAVE M, Jhaveri KL, Kaufman PA, Aftimos P, et al
    Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
    Breast Cancer Res. 2025 Dec 21. doi: 10.1186/s13058-025-02168.
    >> Share

  163. CORREIA BF, Grosa D, Salvador R, Brites I, et al
    Neutrophils matter: new clinical insights on their role in the progression of metastatic breast cancer.
    Breast Cancer Res. 2025;27:223.
    >> Share

  164. WANG D, Luo S, Yu R, Wen D, et al
    ALDH3A2 targets arachidonic acid to promote cell metastasis in TNBC via AMPK/m-TOR signaling pathway.
    Breast Cancer Res. 2025;27:217.
    >> Share

  165. BARDWELL SPELTZ L, Ghosh K, Visscher DW, Scott CG, et al
    Histologic correlates of background parenchymal uptake on molecular breast imaging.
    Breast Cancer Res. 2025;27:216.
    >> Share

  166. HU S, Ji A, Wang M, Li X, et al
    MAP3K1/MAP2K4 mutations drive breast cancer progression by compensating for TP53 loss through inactivation of the JNK2-p53-FOSL1 axis.
    Breast Cancer Res. 2025 Dec 16. doi: 10.1186/s13058-025-02195.
    >> Share

  167. GUHA A, Sultana J, Bhuniya A, Chakravarti M, et al
    Tumor-educated-platelets interact with breast cancer-stem-cells via P-selectin-PSGL1 and ensure stemness and metastasis through WNT-beta-catenin-VEGF-VEGFR2 intra-cellular signaling: therapeutic modulation by aspirin.
    Breast Cancer Res. 2025 Dec 15. doi: 10.1186/s13058-025-02185.
    >> Share

  168. ALIM R, Akalanka HMK
    Metformin and its derivatives in breast cancer: from glycaemic control to tumor-intrinsic pathways.
    Breast Cancer Res. 2025 Dec 12. doi: 10.1186/s13058-025-02194.
    >> Share

  169. WANG X, Zhou Q, Wang P, Bao S, et al
    Nuclear PD-L1 drives IFN-gamma-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E.
    Breast Cancer Res. 2025 Dec 12. doi: 10.1186/s13058-025-02193.
    >> Share

  170. KUBECZKO M, d'Amico A, Chrabanski O, Handkiewicz-Junak D, et al
    Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02191.
    >> Share

  171. NASRAZADANI A, Tidwell RS, Kai M, Lim B, et al
    Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02162.
    >> Share

  172. DE LA FUENTE LR, Law AMK, Rangel-Sanchez L, Venhuizen J, et al
    Modelling the metastatic immune microenvironment in triple-negative breast cancer.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02186.
    >> Share

  173. YANG L, An M, Song H, Zhang X, et al
    Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer.
    Breast Cancer Res. 2025 Dec 9. doi: 10.1186/s13058-025-02190.
    >> Share

  174. SCHREURS MAC, Timmermans AM, Carpenter MA, Smid M, et al
    APOBEC3B protein expression associates with poor prognosis for breast cancer patients with ER-positive disease.
    Breast Cancer Res. 2025 Dec 9. doi: 10.1186/s13058-025-02167.
    >> Share

  175. HE M, Song K, Luo Y, Lai G, et al
    Integrative multi-omics reveals common and distinct pathogenic mechanisms and preoperative diagnostic signatures in breast fibroepithelial lesions.
    Breast Cancer Res. 2025;27:214.
    >> Share

  176. ZHANG W, Zhang S, You J, Li F, et al
    Attention-based multimodal fusion transformer for predicting the efficacy of neoadjuvant therapy in breast cancer: a cross-institutional retrospective study.
    Breast Cancer Res. 2025 Dec 6. doi: 10.1186/s13058-025-02181.
    >> Share

  177. HSU L, Siegel J, Nasarre P, Oberholtzer N, et al
    Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-Upsilon reprograms tumor-associated macrophages to suppress triple negative breast cancer.
    Breast Cancer Res. 2025;27:209.
    >> Share

  178. CHANCHOU M, Mouret-Reynier MA, Molnar I, Deshayes E, et al
    (18)F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.
    Breast Cancer Res. 2025;28:2.
    >> Share

  179. CHATSATOURIAN C, Lo Faro V, Karlsson T, Hadizadeh F, et al
    Breast cancer risk during oral contraceptive use in women with high polygenic risk.
    Breast Cancer Res. 2025 Dec 1. doi: 10.1186/s13058-025-02177.
    >> Share

    November 2025
  180. STEEN S, Karlsson E, Bjornheden I, Rask G, et al
    Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study.
    Breast Cancer Res. 2025;27:213.
    >> Share

  181. DEVAUX A, Beniuga G, Delree P, Quaghebeur C, et al
    Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer.
    Breast Cancer Res. 2025;27:212.
    >> Share

  182. DONG H, Zhou M, Sun Q, Ren Y, et al
    Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities.
    Breast Cancer Res. 2025;27:210.
    >> Share

  183. XIA X, He X, Tang M, Chen Y, et al
    CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.
    Breast Cancer Res. 2025;27:211.
    >> Share

  184. XU NN, Barnard ME, Holder EX, Rosenberg L, et al
    Perceived racial discrimination in health care in relation to late stage at breast cancer diagnosis.
    Breast Cancer Res. 2025;27:208.
    >> Share

  185. LI S, Jiang QL, Gong HZ, Zeng Y, et al
    Autoimmune thyroiditis promotes breast cancer progression: exploratory role of thyroid hormone receptor beta signaling disruption.
    Breast Cancer Res. 2025 Nov 24. doi: 10.1186/s13058-025-02184.
    >> Share

  186. LEE J, Park EY, Lee WJ
    Cardiovascular disease risk following radiotherapy among breast cancer survivors: a nationwide cohort study in South Korea.
    Breast Cancer Res. 2025 Nov 23. doi: 10.1186/s13058-025-02178.
    >> Share

  187. MARIAPUN S, Eriksson M, Tai MC, Mohd Taib NA, et al
    Genome-wide association study of Asian women identifies putative mammographic density-associated loci.
    Breast Cancer Res. 2025;27:207.
    >> Share

  188. CHAURASIA AK, Toohey PW, Bennett MT, Harris HC, et al
    Automated quantification of Ki-67 expression in breast cancer from H&E-stained slides using a transformer-based regression model.
    Breast Cancer Res. 2025;27:206.
    >> Share

  189. QIU Y, Zhang R, Liu S, Wu L, et al
    Dynamic tumor-infiltrating lymphocytes predicts survival in HR+/HER2- early breast cancer: a pre-to-post neoadjuvant chemotherapy study.
    Breast Cancer Res. 2025;27:205.
    >> Share

  190. JOUINES C, Lo Monaco P, Gaucherot A, Radermecker J, et al
    Fibrillarin-mediated ribosomal RNA maturation is a novel therapeutic vulnerability in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:202.
    >> Share

  191. EDLUND J, Wu WY, Gustafsson M, Linden J, et al
    Exposure to ambient air pollution during pregnancy and risk of early-onset breast cancer.
    Breast Cancer Res. 2025;27:203.
    >> Share

  192. YANG Z, Lou H, Huang Y, Guo L, et al
    Integrating bulk and single-cell RNA sequencing analysis to reveal characterization of mechanical stimulus-related genes and prognostic signatures in breast cancer.
    Breast Cancer Res. 2025;27:204.
    >> Share

  193. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea-Baz N, Pachon-Olmos V, et al
    Correction: Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index.
    Breast Cancer Res. 2025;27:201.
    >> Share

  194. YU S, Zhou Y, Zhang S, He F, et al
    The role and prognostic value of mitochondria-related gene PARK7 in breast cancer.
    Breast Cancer Res. 2025;27:200.
    >> Share

  195. WANG Y, Ma Y, Liu A, Zhao M, et al
    Longitudinal contrast-enhanced cone beam breast computed tomography for monitoring treatment response in breast cancer neoadjuvant therapy: a comprehensive assessment.
    Breast Cancer Res. 2025;27:199.
    >> Share

  196. XIE G, Zhang G, Cui J, Zhang Y, et al
    Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer.
    Breast Cancer Res. 2025;27:198.
    >> Share

  197. AZHAR M, Soto F, Su A, Gonzalez NAV, et al
    Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study.
    Breast Cancer Res. 2025;27:197.
    >> Share

  198. SHEN J, Guan Y, Boyle J, Fuemmeler BF, et al
    Neighborhood deprivation, breast cancer outcomes and stress-related gene expression in leukocytes and tumor tissue.
    Breast Cancer Res. 2025;27:196.
    >> Share

  199. SARCINELLA A, Kholia S, Femmino S, Cedrino M, et al
    IL-3/STAT5/miR-155-5p axis supports stem-related pathway reprogramming in TNBC.
    Breast Cancer Res. 2025;27:195.
    >> Share

  200. KANG E, Shin IB, Jung JJ, Byeon J, et al
    Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast.
    Breast Cancer Res. 2025;27:194.
    >> Share

    October 2025
  201. CHO Y, Jang Y, Woo HY, Chang Y, et al
    Longitudinal changes in mammographic density and reproductive hormones during the menopausal transition in middle-aged Korean women: effect modification by obesity.
    Breast Cancer Res. 2025;27:193.
    >> Share

  202. VASSON F, Matta K, Biessy C, S Antoniussen C, et al
    Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition.
    Breast Cancer Res. 2025;27:192.
    >> Share

  203. KRASNOW NA, Jayaraj M, Salans M, Kuwahara K, et al
    Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study.
    Breast Cancer Res. 2025;27:191.
    >> Share

  204. LIU M, Zou L, Zhang N, Zhou W, et al
    Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial.
    Breast Cancer Res. 2025;27:190.
    >> Share

  205. DAS GUPTA S, Getz K, Hernandez Lopez J, Bennett DL, et al
    Associations of early-adulthood adiposity with breast parenchymal tissue complexity within premenopausal women.
    Breast Cancer Res. 2025;27:188.
    >> Share

  206. DEBINSKI W, Fink KN, Rossmeisl J, Mott RT, et al
    Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.
    Breast Cancer Res. 2025;27:189.
    >> Share

  207. COLEMAN MF, McDonell SB, Eisenbeis LK, Devericks EN, et al
    The nonsteroidal anti-inflammatory drug sulindac reverses obesity-driven immunosuppression and triple-negative breast cancer progression.
    Breast Cancer Res. 2025;27:186.
    >> Share

  208. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea-Baza-Baz N, Pachon-Olmos V, et al
    Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index.
    Breast Cancer Res. 2025;27:187.
    >> Share

  209. GUO Y, Chen M, Yuan Q, Huang J, et al
    Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer.
    Breast Cancer Res. 2025;27:184.
    >> Share

  210. SAINI M, Parvar TA, Graham C, Larson NB, et al
    Deep learning-powered multi-parametric ultrasound for classifying metastatic versus reactive axillary lymph nodes.
    Breast Cancer Res. 2025;27:185.
    >> Share

  211. RAVANI VL, Bagheri Z, Brufsky AM, Michelon I, et al
    Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:183.
    >> Share

  212. CUI W, Fan M, Li L
    Morphological analysis of tumor microenvironment in HER2-positive breast cancer: predicting response to neoadjuvant chemotherapy on histopathological images.
    Breast Cancer Res. 2025;27:182.
    >> Share

  213. PARK I, Shin SJ, Go H, Ko J, et al
    Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence.
    Breast Cancer Res. 2025;27:181.
    >> Share

  214. NOROUZI F, Eini P, Tahmasebi S
    The role of NETosis in breast cancer: mechanistic insights and biomarker potential.
    Breast Cancer Res. 2025;27:180.
    >> Share

  215. MARCHENKO N, Nesbitt NM, Alexandrova E, Reisz JA, et al
    Biliverdin reductase B as a new target in breast cancer.
    Breast Cancer Res. 2025;27:179.
    >> Share

  216. LIEN HC, Li YC, Yun-Ju Huang R, Chen KC, et al
    Carcinomas exhibiting epithelial-mesenchymal transition manifest an M2 macrophage-enriched tumor immune microenvironment.
    Breast Cancer Res. 2025;27:177.
    >> Share

  217. CAO A, Fumagalli IA, Chen WY, Llanos AAM, et al
    Association between thoracic adiposity and survival in non-metastatic breast cancer.
    Breast Cancer Res. 2025;27:176.
    >> Share

  218. ZHANG R, Wang K, Wang S, Wang C, et al
    Multimodal deep learning model for prediction of breast cancer recurrence risk and correlation with oncotype DX.
    Breast Cancer Res. 2025;27:178.
    >> Share

  219. CHEN XY, Wang Y, Li DR, Liu BQ, et al
    Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study.
    Breast Cancer Res. 2025;27:175.
    >> Share

  220. SHEN J, Liu Y, Liu A, Gu X, et al
    Artificial intelligence-assisted ultrasound screening for breast cancer in China: a prospective, clustered, controlled, population-based study.
    Breast Cancer Res. 2025;27:173.
    >> Share

  221. MARTIN-BEJARANO P, Sanchez-Tapia EM, Jessica P, Martin-Gomez T, et al
    Functional characterization of BRCA1 variants of unknown significance using homologous recombination repair assays.
    Breast Cancer Res. 2025;27:174.
    >> Share

  222. AL DLALI M, Al Amri B, Al Zeheimi N, Al Busaidi R, et al
    Genomic landscape of cancer driver genes in Omani breast cancers: a pilot study.
    Breast Cancer Res. 2025;27:172.
    >> Share

    September 2025
  223. FONTANA A, Barbano R, Pasculli B, Mazza T, et al
    Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients.
    Breast Cancer Res. 2025;27:170.
    >> Share

  224. MAHMOUD MA, Winham SJ, Scott CG, Ehsan S, et al
    Interplay of BMI and volumetric breast density measures and breast cancer risk for black and white women.
    Breast Cancer Res. 2025;27:167.
    >> Share

  225. FANUCCI K, Yeh ED, Shi R, Qin L, et al
    Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
    Breast Cancer Res. 2025;27:171.
    >> Share

  226. KOYAMA Y, Muguruma M, Horimoto Y, Narui K, et al
    Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort study.
    Breast Cancer Res. 2025;27:169.
    >> Share

  227. VERMA D, Nandi D, Parida S, Saxena A, et al
    An enteropathogenic microbial toxin modulates the breast cancer epigenome resulting in concurrent silencing of tumor suppressor genes.
    Breast Cancer Res. 2025;27:163.
    >> Share

  228. SUNG H, Jiang C, Jatoi I, Jemal A, et al
    Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.
    Breast Cancer Res. 2025;27:164.
    >> Share

  229. WONG C, Yang Q, Liang Y, Wei Z, et al
    AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study.
    Breast Cancer Res. 2025;27:166.
    >> Share

  230. YANG Z, Lian X, Luo Y, Ye Q, et al
    Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation.
    Breast Cancer Res. 2025;27:165.
    >> Share

  231. OGONY JW, Pacheco-Spann LM, Arnold A, Cabezas JV, et al
    A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression.
    Breast Cancer Res. 2025;27:162.
    >> Share

  232. WANG M, Mo S, Li G, Zheng J, et al
    Deep learning and radiomics integration of photoacoustic/ultrasound imaging for non-invasive prediction of luminal and non-luminal breast cancer subtypes.
    Breast Cancer Res. 2025;27:161.
    >> Share

  233. KVIST A, Kampe A, Torngren T, Tesi B, et al
    Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer.
    Breast Cancer Res. 2025;27:160.
    >> Share

  234. BOYACI C, Sun W, Hartman J, Acs B, et al
    Global scoring method of Ki67 immunohistochemistry in breast cancer demonstrates improved concordance using real-world multi-institutional data.
    Breast Cancer Res. 2025;27:159.
    >> Share

  235. WU HC, Liao Y, Lai Y, Lin PH, et al
    The plasma proteome and breast cancer risk.
    Breast Cancer Res. 2025;27:157.
    >> Share

  236. LI Y, Liu W, Yu Y, Wang Y, et al
    Early thelarche, reproductive hormones, and MRI-based breast density: a prospective study in China.
    Breast Cancer Res. 2025;27:158.
    >> Share

    August 2025
  237. TRINH L, Parks J, McDonald T, Roth A, et al
    Pre-diagnostic serum metabolome and breast cancer risk: a nested case-control study.
    Breast Cancer Res. 2025;27:156.
    >> Share

  238. ZHANG F, de Bock GH, Landman GW, Zhang Q, et al
    Longitudinal changes in metabolism-related metrics and breast cancer risk: a general population study.
    Breast Cancer Res. 2025;27:155.
    >> Share

  239. CHEN CH, Chen IC, Hsu CL, Lu TP, et al
    Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses.
    Breast Cancer Res. 2025;27:154.
    >> Share

  240. WESTENEND PJ, Meurs C, Fernandez G, Prastawa M, et al
    External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.
    Breast Cancer Res. 2025;27:152.
    >> Share

  241. HAMILTON E, Pluard T, Wang JS, Morikawa A, et al
    Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2025;27:151.
    >> Share

  242. KLAHR MP, Faheem K, Raghunathan RR, Wooster M, et al
    Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.
    Breast Cancer Res. 2025;27:150.
    >> Share

  243. PATEL R, Weil E, Bugamelli S, Carroll E, et al
    Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.
    Breast Cancer Res. 2025;27:147.
    >> Share

  244. DANKNER M, Ouellet V, Lafon J, Ezzeddine R, et al
    Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes.
    Breast Cancer Res. 2025;27:149.
    >> Share

  245. REEVES KW, Oulhote Y, Grandjean P, Nielsen F, et al
    Associations of perfluoroalkyl substances (PFAS) with terminal ductal lobular unit involution of the normal breast.
    Breast Cancer Res. 2025;27:148.
    >> Share

  246. RAVANI LV, Bagheri Z, Brufsky AM, Michellon I, et al
    Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:146.
    >> Share

  247. HUANG B, Zhang Y, Chen Z, Yuan Y, et al
    Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination.
    Breast Cancer Res. 2025;27:145.
    >> Share

  248. PARISSENTI AM, Pritzker LB, Dahle MA, Gythfeldt HVL, et al
    High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2025;27:143.
    >> Share

  249. SLEDGE GWJ, Xiu J, Solzak JP, Ribeiro J, et al
    Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.
    Breast Cancer Res. 2025;27:144.
    >> Share

  250. HAYASHI K, Hoshii T, Ning M, Matsumoto M, et al
    Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K.
    Breast Cancer Res. 2025;27:142.
    >> Share

  251. LOPEZ-MIRANDA E, Perez-Garcia JM, Gion M, Ribelles N, et al
    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.
    Breast Cancer Res. 2025;27:141.
    >> Share

    July 2025
  252. LIU N, van der Velde JJS, Ramdjielal S, Koedoot E, et al
    Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC.
    Breast Cancer Res. 2025;27:140.
    >> Share

  253. ZAFAR S, Badshah Y, Shabbir M, Mussarat U, et al
    Missense variants in PRKCD: elucidating their potential association with breast cancer.
    Breast Cancer Res. 2025;27:139.
    >> Share

  254. HERNANDEZ A, Puppala A, Hedlich-Dwyer J, Mukherjee N, et al
    Short-term consumption of the modified standard American diet perturbed the metabolic balance and altered DNA damage in MMTV-PyMT transgenic mice.
    Breast Cancer Res. 2025;27:138.
    >> Share

  255. LEE CH, Park SY, Lee JS, Kim DS, et al
    MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:136.
    >> Share

  256. BOETTCHER L, Greimeier S, Borgmann K, Mughal SS, et al
    Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer.
    Breast Cancer Res. 2025;27:137.
    >> Share

  257. DUAN F, Hua X, Lu W, Gui X, et al
    Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.
    Breast Cancer Res. 2025;27:135.
    >> Share

  258. WHI W, Shin J, Kim JY, Ahn HK, et al
    Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.
    Breast Cancer Res. 2025;27:134.
    >> Share

  259. TUOKKOLA JE, Reese LE, Wang Y, O'Connor CH, et al
    Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.
    Breast Cancer Res. 2025;27:132.
    >> Share

  260. DO TTN, Block I, Burton M, Sorensen KP, et al
    Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up.
    Breast Cancer Res. 2025;27:133.
    >> Share

  261. SKOURTI E, Seip K, Mensali N, Jabeen S, et al
    Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.
    Breast Cancer Res. 2025;27:131.
    >> Share

  262. JONG CL, Siesling S, Puts GCWM, Jager A, et al
    The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study.
    Breast Cancer Res. 2025;27:129.
    >> Share

  263. HOLM JB, Skovbjerg SB, Nielsen HM, Christiansen P, et al
    The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer.
    Breast Cancer Res. 2025;27:130.
    >> Share

  264. LUO Q, Zhang L, Hao Y, Xu C, et al
    Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4.
    Breast Cancer Res. 2025;27:128.
    >> Share

  265. RIZVI N, Mucaki EJ, Salmini EL, Zhang M, et al
    Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.
    Breast Cancer Res. 2025;27:127.
    >> Share

  266. DENNAOUI R, Radler PD, Wicker MN, Vistisen K, et al
    Overexpression of TSG101 causes the development of adenosquamous mammary carcinoma.
    Breast Cancer Res. 2025;27:126.
    >> Share

  267. XIONG G, He D, Napier D, Chen J, et al
    Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue.
    Breast Cancer Res. 2025;27:125.
    >> Share

  268. ZENG Y, Xu Z, Huang J, Yi Q, et al
    THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:124.
    >> Share

  269. HAMILTON EP, Patel MR, Borges VF, Meisel JL, et al
    Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
    Breast Cancer Res. 2025;27:119.
    >> Share

  270. MULDER CV, Jongbloed EM, Liefaard MC, Makrodimitris S, et al
    A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.
    Breast Cancer Res. 2025;27:120.
    >> Share

  271. HUANG Z, Mo S, Li G, Tian H, et al
    Prognosticating axillary lymph node metastasis in breast cancer through integrated photoacoustic imaging, ultrasound, and clinical parameters.
    Breast Cancer Res. 2025;27:123.
    >> Share

  272. POURALI G, Liu M, Sherpa SS, Hardi A, et al
    Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials.
    Breast Cancer Res. 2025;27:118.
    >> Share

  273. BULLOCK E, Rozyczko A, Shabbir S, Tsoupi I, et al
    Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.
    Breast Cancer Res. 2025;27:121.
    >> Share

  274. HIS M, Baggio I, Chabaud S, Tassy L, et al
    Long-term weight change among breast cancer patients treated with chemotherapy: a longitudinal study over 13 years.
    Breast Cancer Res. 2025;27:117.
    >> Share

  275. CHAKI M, Benrashid M, Puri S, Sivakumar S, et al
    Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
    Breast Cancer Res. 2025;27:122.
    >> Share

    June 2025
  276. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2025;27:116.
    >> Share

  277. LEON-FERRE RA, Dimitroff K, Yau C, Giridhar KV, et al
    Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Breast Cancer Res. 2025;27:115.
    >> Share

  278. RYU S, Kim HS, Lee S, Yoon SH, et al
    Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models.
    Breast Cancer Res. 2025;27:113.
    >> Share

  279. CORRADO A, Lorito N, Anemone A, Carella A, et al
    In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer.
    Breast Cancer Res. 2025;27:112.
    >> Share

  280. CAIRAT M, Olesen M, Olivier E, Pottegard A, et al
    Systemic glucocorticoids and the risk of breast cancer in a large nationwide case-control study.
    Breast Cancer Res. 2025;27:114.
    >> Share

  281. CHANG AC, Balic M, Bartholow T, Bhargava R, et al
    Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer.
    Breast Cancer Res. 2025;27:111.
    >> Share

  282. CHAO X, Wu Y, Cai X, He J, et al
    Exploratory multi-cohort, multi-reader study on the clinical utility of a deep learning model for transforming cryosectioned to formalin-fixed, paraffin-embedded (FFPE) images in breast lesion diagnosis.
    Breast Cancer Res. 2025;27:110.
    >> Share

  283. IESATO A, Suzuka J, Otsuji K, Osako T, et al
    Axillary adipose tissue-derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer.
    Breast Cancer Res. 2025;27:109.
    >> Share

  284. WILHELM A, Flynn C, Hammer E, Roessler J, et al
    Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.
    Breast Cancer Res. 2025;27:107.
    >> Share

  285. GAO L, Zhang L, Liu J, Wang L, et al
    Discovery and validation of cell-free DNA methylation markers for specific diagnosis, differentiation from benign tumors, and prognosis of breast cancer.
    Breast Cancer Res. 2025;27:108.
    >> Share

  286. VAN BAELEN K, Nguyen HL, Richard F, Zels G, et al
    Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
    Breast Cancer Res. 2025;27:106.
    >> Share

  287. ZHONG X, Deng J, Lu P, Zuo Z, et al
    Wearable device for axillary lymph node screening in breast cancer based on infrared thermography and artificial intelligence.
    Breast Cancer Res. 2025;27:104.
    >> Share

  288. ODZER N, Chehayeb RJ, Schellhorn SE, Lustberg M, et al
    Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States.
    Breast Cancer Res. 2025;27:102.
    >> Share

  289. DENNIS SR, Tsukioki T, Cottone G, Zhou W, et al
    DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls.
    Breast Cancer Res. 2025;27:103.
    >> Share

  290. DING P, Pei S, Zhai Y, Qu Z, et al
    Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.
    Breast Cancer Res. 2025;27:101.
    >> Share

  291. CHEN C, Yao H, Jie H, Liang Z, et al
    SENP5 drives breast cancer progression through deSUMOYlation of CDK1.
    Breast Cancer Res. 2025;27:100.
    >> Share

  292. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Correction: Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2025;27:99.
    >> Share

  293. HU C, Zhang S, Duan F, Huang X, et al
    Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.
    Breast Cancer Res. 2025;27:96.
    >> Share

  294. ZHONG HJ, Zhen Y, Chen S, Shi W, et al
    Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.
    Breast Cancer Res. 2025;27:97.
    >> Share

    May 2025
  295. LIU PH, Tsai CF, Hsu YC, Wu CY, et al
    Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study.
    Breast Cancer Res. 2025;27:95.
    >> Share

  296. ROY R, Schunkert EM, Olivova P, Gilar M, et al
    Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.
    Breast Cancer Res. 2025;27:94.
    >> Share

  297. XUAN W, Li W, Ke L, Shen Y, et al
    Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes.
    Breast Cancer Res. 2025;27:93.
    >> Share

  298. GAO Y, Zuo L, Zheng Y, Sun K, et al
    NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Breast Cancer Res. 2025;27:92.
    >> Share

  299. SPYCHALSKI GB, Lin AA, Yang SJ, Shen H, et al
    miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer.
    Breast Cancer Res. 2025;27:90.
    >> Share

  300. MUNHOZ J, Newell M, Goruk S, Ghosh S, et al
    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial.
    Breast Cancer Res. 2025;27:91.
    >> Share

  301. KIM H, Chun JW, Hwang J, Yun SG, et al
    Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study.
    Breast Cancer Res. 2025;27:89.
    >> Share

  302. MAVADDAT N, Frost D, Zhao E, Barnes DR, et al
    Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE.
    Breast Cancer Res. 2025;27:87.
    >> Share

  303. CHEUNG AM, Wang D, Quintayo MA, Yerofeyeva Y, et al
    Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping.
    Breast Cancer Res. 2025;27:88.
    >> Share

  304. HUANG Y, Cao Y, Chen H, Lan X, et al
    Quantifying tumor morphological complexity based on pretreatment MRI fractal analysis for predicting pathologic complete response and survival in breast cancer: a retrospective, multicenter study.
    Breast Cancer Res. 2025;27:86.
    >> Share

  305. JEONG J, Yoo K, Lee J, Shin JH, et al
    Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer.
    Breast Cancer Res. 2025;27:85.
    >> Share

  306. KIM JS, Lee JH, Yeon Y, An D, et al
    Correction: Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
    Breast Cancer Res. 2025;27:84.
    >> Share

  307. MOSHINA N, Gjesvik J, Hovda T, Koch HW, et al
    Mammographic density by time and breast: a retrospective cohort study from BreastScreen Norway.
    Breast Cancer Res. 2025;27:83.
    >> Share

  308. DIAZ-SANTANA MV, Park J, Rogers M, O'Brien KM, et al
    Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort.
    Breast Cancer Res. 2025;27:82.
    >> Share

  309. CARLSON EG, Lopez JC, Yamaguchi Y, Gibson J, et al
    CD105(+) fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiation.
    Breast Cancer Res. 2025;27:81.
    >> Share

  310. VENETIS K, Cursano G, Scafetta R, Giachetti PPMB, et al
    ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.
    Breast Cancer Res. 2025;27:79.
    >> Share

  311. XU Z, Zhong S, Gao Y, Huo J, et al
    Optimizing breast lesions diagnosis and decision-making with a deep learning fusion model integrating ultrasound and mammography: a dual-center retrospective study.
    Breast Cancer Res. 2025;27:80.
    >> Share

  312. ULANDAY KT, Topaz M, Shekelle J, Gibbons M, et al
    Cancers missed, women dismissed yet persist: natural language processing of online forums.
    Breast Cancer Res. 2025;27:78.
    >> Share

  313. ROBINSON TJ, Liveringhouse CL, Wilson C, Friedman S, et al
    Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.
    Breast Cancer Res. 2025;27:77.
    >> Share

  314. WU SY, Sharma S, Wu K, Tyagi A, et al
    Retraction Note: Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
    Breast Cancer Res. 2025;27:75.
    >> Share

  315. MA X, Zhang B, Yin X, Yang S, et al
    CPT1A/HIF-1alpha positive feedback loop induced fatty acid oxidation metabolic pathway contributes to the L-ascorbic acid-driven angiogenesis in breast cancer.
    Breast Cancer Res. 2025;27:74.
    >> Share

  316. HEUMANN P, Benner A, Behrens S, Chang-Claude J, et al
    Prognostic value of cancer-related fatigue at the end of radiotherapy for overall survival >/= 10 years in women with breast cancer.
    Breast Cancer Res. 2025;27:76.
    >> Share

  317. VETHENCOURT A, Trinidad EM, Dorca E, Petit A, et al
    Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
    Breast Cancer Res. 2025;27:68.
    >> Share

  318. MANGIOLA S, Brown R, Zhan C, Berthelet J, et al
    Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.
    Breast Cancer Res. 2025;27:73.
    >> Share

  319. WANG X, Huang Y, Shi J, Cao Y, et al
    Biomechanical parameters quantified by MR elastography for predicting response to neoadjuvant chemotherapy and disease-free survival in breast cancer: a prospective longitudinal study.
    Breast Cancer Res. 2025;27:72.
    >> Share

  320. PHI LTH, Cheng Y, Funakoshi Y, Bertucci F, et al
    AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
    Breast Cancer Res. 2025;27:70.
    >> Share

  321. WANG B, Chen X, Li H, Sun J, et al
    8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.
    Breast Cancer Res. 2025;27:71.
    >> Share

  322. HEYDARI S, Tajik F, Safaei S, Kamani F, et al
    The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review.
    Breast Cancer Res. 2025;27:69.
    >> Share

  323. BRANTLEY KD, Jones ME, Tamimi RM, Rosner BA, et al
    Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts.
    Breast Cancer Res. 2025;27:67.
    >> Share

  324. KIM SC, Kim GH, Park JH, Lee KH, et al
    Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.
    Breast Cancer Res. 2025;27:66.
    >> Share

  325. DENG N, Kang W, Du J, Rong X, et al
    Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein.
    Breast Cancer Res. 2025;27:63.
    >> Share

  326. COMINO-MENDEZ I, Velasco-Suelto J, Pascual J, Lopez-Lopez E, et al
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.
    Breast Cancer Res. 2025;27:65.
    >> Share

  327. DONG M, Chen J, Lu N, Wang S, et al
    Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis.
    Breast Cancer Res. 2025;27:64.
    >> Share

    April 2025
  328. KONG L, Hu S, Zhao Y, Huang Y, et al
    Neutrophil extracellular traps induced by neoadjuvant chemotherapy of breast cancer promotes vascular endothelial damage.
    Breast Cancer Res. 2025;27:61.
    >> Share

  329. LI X, Lin Z, Qiu C, Zhang Y, et al
    Transfer learning drives automatic HER2 scoring on HE-stained WSIs for breast cancer: a multi-cohort study.
    Breast Cancer Res. 2025;27:62.
    >> Share

  330. MESA-EGUIAGARAY I, Wild SH, Williams LJ, Jin K, et al
    Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland.
    Breast Cancer Res. 2025;27:59.
    >> Share

  331. DAI J, Rozenblit M, Li X, Shan NL, et al
    Genomic alterations in normal breast tissues preceding breast cancer diagnosis.
    Breast Cancer Res. 2025;27:60.
    >> Share

  332. KIM JS, Lee JH, Yeon Y, An DY, et al
    Predicting Nottingham grade in breast cancer digital pathology using a foundation model.
    Breast Cancer Res. 2025;27:58.
    >> Share

  333. DU J, Shi J, Sun D, Wang Y, et al
    Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin-eosin-stained slides.
    Breast Cancer Res. 2025;27:57.
    >> Share

  334. ZHAO Y, Song Y, Li X, Guo A, et al
    Retraction Note: Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
    Breast Cancer Res. 2025;27:56.
    >> Share

  335. SCHOEMAKER MJ, Ellington T, Nichols HB, Wright LB, et al
    Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women.
    Breast Cancer Res. 2025;27:55.
    >> Share

  336. HAN J, Zhai X, Tao X, Li Y, et al
    Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.
    Breast Cancer Res. 2025;27:54.
    >> Share

  337. YAGHJYAN L, Heng YJ, Sardella BR, Murthy D, et al
    Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue.
    Breast Cancer Res. 2025;27:53.
    >> Share

  338. DU S, Xie W, Gao S, Zhao R, et al
    Early prediction of neoadjuvant therapy response in breast cancer using MRI-based neural networks: data from the ACRIN 6698 trial and a prospective Chinese cohort.
    Breast Cancer Res. 2025;27:52.
    >> Share

  339. WANG Y, Jiang Y, Ding F, Lu J, et al
    Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy.
    Breast Cancer Res. 2025;27:51.
    >> Share

  340. KAISER E, Weber R, Hirschstein M, Mazid H, et al
    Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study.
    Breast Cancer Res. 2025;27:50.
    >> Share

    March 2025
  341. WANG F, Li W, Han G, Xie J, et al
    A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.
    Breast Cancer Res. 2025;27:47.
    >> Share

  342. YUAN X, Rosen JM
    Histone acetylation modulators in breast cancer.
    Breast Cancer Res. 2025;27:49.
    >> Share

  343. LIPERT BA, Siemens KN, Khan A, Airey R, et al
    CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance.
    Breast Cancer Res. 2025;27:48.
    >> Share

  344. WU X, Li Y, Chen J, Chen J, et al
    Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features.
    Breast Cancer Res. 2025;27:27.
    >> Share

  345. KRESOVICH JK, Reid BM, O'Brien KM, Xu Z, et al
    DNA methylation-predicted plasma protein levels and breast cancer risk.
    Breast Cancer Res. 2025;27:46.
    >> Share

  346. LV H, Yue J, Zhang Q, Xu F, et al
    Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China.
    Breast Cancer Res. 2025;27:45.
    >> Share

  347. FORTUNATO A, Mallo D, Cisneros L, King LM, et al
    Evolutionary measures show that recurrence of DCIS is distinct from progression to breast cancer.
    Breast Cancer Res. 2025;27:43.
    >> Share

  348. BERGHOLTZ H, Norum JH, Lien TG, Skrede ML, et al
    B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.
    Breast Cancer Res. 2025;27:44.
    >> Share

  349. BAEK SH, Lee MJ, Kook Y, Bae SJ, et al
    Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer.
    Breast Cancer Res. 2025;27:42.
    >> Share

  350. LI M, Zhou S, Lv H, Cai M, et al
    Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations.
    Breast Cancer Res. 2025;27:41.
    >> Share

  351. INGLE JN, Suman VJ, Solanki MH, Passow MR, et al
    Evaluation of the androgen receptor in patients with ERalpha-positive early breast cancer treated with adjuvant tamoxifen +/- fluoxymesterone.
    Breast Cancer Res. 2025;27:40.
    >> Share

  352. DE MORAES FCA, de Castro Ribeiro CHD, Pessoa FDDL, Chaves JR, et al
    Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.
    Breast Cancer Res. 2025;27:39.
    >> Share

  353. ZHANG D, Jahanfar S, Rabinowitz JB, Dower J, et al
    Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2025;27:38.
    >> Share

  354. HECKENBACH I, Peila R, Benz C, Weinmann S, et al
    Cellular senescence predicts breast cancer risk from benign breast disease biopsy images.
    Breast Cancer Res. 2025;27:37.
    >> Share

  355. DENT R, Cortes J, Park YH, Munoz-Couselo E, et al
    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.
    Breast Cancer Res. 2025;27:35.
    >> Share

  356. VIART NM, Renault AL, Eon-Marchais S, Jiao Y, et al
    Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile.
    Breast Cancer Res. 2025;27:36.
    >> Share

  357. LEE J, Ham S, Kim N, Park HS, et al
    Development of a deep learning-based model for guiding a dissection during robotic breast surgery.
    Breast Cancer Res. 2025;27:34.
    >> Share

  358. WARD AV, Riley D, Cosper KE, Finlay-Schultz J, et al
    Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells.
    Breast Cancer Res. 2025;27:32.
    >> Share

  359. USUI T, Miyake T, Watabe T, Kato H, et al
    Preclinical evaluation of (64)Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.
    Breast Cancer Res. 2025;27:33.
    >> Share

  360. WU S, Jiang B, Li Z, Tang Y, et al
    Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.
    Breast Cancer Res. 2025;27:31.
    >> Share

    February 2025
  361. FENG X, Shi Y, Wu M, Cui G, et al
    Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model.
    Breast Cancer Res. 2025;27:30.
    >> Share

  362. SHI Q, Yang W, Ouyang Y, Liu Y, et al
    Correction: CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
    Breast Cancer Res. 2025;27:28.
    >> Share

  363. WU X, Xia Y, Lou X, Huang K, et al
    Decoding breast cancer imaging trends: the role of AI and radiomics through bibliometric insights.
    Breast Cancer Res. 2025;27:29.
    >> Share

  364. MARKS JR, Zhang D, Hardman T, Chen YY, et al
    Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).
    Breast Cancer Res. 2025;27:26.
    >> Share

  365. DUIVON M, Christy F, Thomas E, Lequesne J, et al
    Interaction between APOE E4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.
    Breast Cancer Res. 2025;27:25.
    >> Share

  366. SABETI S, Larson NB, Boughey JC, Stan DL, et al
    Ultrasound-based quantitative microvasculature imaging for early prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res. 2025;27:24.
    >> Share

  367. HUNTER NB, Peterson LM, Specht JM, Mankoff DA, et al
    Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:23.
    >> Share

  368. SCHMIDT G, Gluz O, Christgen M, Reinisch M, et al
    HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
    Breast Cancer Res. 2025;27:22.
    >> Share

  369. ZHANG L, Liu Y, Yang C, Ma J, et al
    Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study.
    Breast Cancer Res. 2025;27:21.
    >> Share

  370. YANG JS, Cao JM, Sun R, Zhou XJ, et al
    SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.
    Breast Cancer Res. 2025;27:20.
    >> Share

  371. LOPEZ M, Spehner L, Andre F, Viot J, et al
    Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
    Breast Cancer Res. 2025;27:19.
    >> Share

  372. WHITMARSH T, Cope W, Carmona-Bozo J, Manavaki R, et al
    Quantifying the tumour vasculature environment from CD-31 immunohistochemistry images of breast cancer using deep learning based semantic segmentation.
    Breast Cancer Res. 2025;27:17.
    >> Share

  373. GETZ KR, Jeon MS, Liu L, Liu L, et al
    Metabolites and lipid species mediate the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women.
    Breast Cancer Res. 2025;27:18.
    >> Share

  374. HENRICKS J, Haddad T, Ahmed O, Schoenhals J, et al
    Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer.
    Breast Cancer Res. 2025;27:16.
    >> Share

    January 2025
  375. SHI Q, Yang W, Ouyang Y, Liu Y, et al
    CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
    Breast Cancer Res. 2025;27:15.
    >> Share

  376. HABERLE L, Erber R, Gass P, Hein A, et al
    Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
    Breast Cancer Res. 2025;27:13.
    >> Share

  377. EHLERS FAI, Blise KE, Betts CB, Sivagnanam S, et al
    Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.
    Breast Cancer Res. 2025;27:14.
    >> Share

  378. DEMICHELE A, Dueck AC, Hlauschek D, Martin M, et al
    Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
    Breast Cancer Res. 2025;27:12.
    >> Share

  379. GABER M, Quentel A, Holmes J, Lepetit C, et al
    Obesity increases DNA damage in the breast epithelium.
    Breast Cancer Res. 2025;27:11.
    >> Share

  380. ZAREAN E, Li S, Wong EM, Makalic E, et al
    Tumour DNA methylation markers associated with breast cancer survival: a replication study.
    Breast Cancer Res. 2025;27:9.
    >> Share

  381. YOUNG KS, Hancock GR, Fink EC, Zigrossi A, et al
    Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.
    Breast Cancer Res. 2025;27:10.
    >> Share

  382. PACAUD R, Thomas S, Chaudhuri S, Lazar A, et al
    Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.
    Breast Cancer Res. 2025;27:8.
    >> Share

  383. AGUILAR D, Garza-Rodriguez ML, Muniz-Garza CE, Nunez FA, et al
    Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.
    Breast Cancer Res. 2025;27:7.
    >> Share

  384. HU K, Wu Y, Huang Y, Zhou M, et al
    Annotation-free deep learning algorithm trained on hematoxylin & eosin images predicts epithelial-to-mesenchymal transition phenotype and endocrine response in estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2025;27:6.
    >> Share

  385. KIM SS, Park I, Kim J, Ka NL, et al
    Secreted LGALS3BP facilitates distant metastasis of breast cancer.
    Breast Cancer Res. 2025;27:4.
    >> Share

  386. MOSTOFSKY E, Buring JE, Come SE, Tung NM, et al
    Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study.
    Breast Cancer Res. 2025;27:5.
    >> Share

  387. PARK J, Chang ES, Kim JY, Chelakkot C, et al
    Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:3.
    >> Share

  388. FANG Z, Ren G, Ke S, Xu Q, et al
    Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study.
    Breast Cancer Res. 2025;27:2.
    >> Share

  389. MAJUMDER S, Mishra S, Shinde N, Cuitino MC, et al
    Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models.
    Breast Cancer Res. 2025;27:1.
    >> Share

    December 2024
  390. PRZANOWSKA RK, Labban N, Przanowski P, Hawes RB, et al
    Patient-derived response estimates from zero-passage organoids of luminal breast cancer.
    Breast Cancer Res. 2024;26:192.
    >> Share

  391. WANG WK, Lin HY, Lin CH, Lee HH, et al
    GRK6 palmitoylation dictates triple-negative breast cancer metastasis via recruiting the beta-Arrestin 2/MAPKs/NF-kappaB signaling axis.
    Breast Cancer Res. 2024;26:193.
    >> Share

  392. LIAO CC, Long Y, Tsai ML, Lin CY, et al
    G-cleave LC3B biosensor: monitoring autophagy and assessing resveratrol's synergistic impact on doxorubicin-induced apoptosis in breast cancer cells.
    Breast Cancer Res. 2024;26:190.
    >> Share

  393. LESLIE SALEWON M, Pathak R, Dooley WC, Squires RA, et al
    Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare.
    Breast Cancer Res. 2024;26:191.
    >> Share

  394. YIANGOU K, Mavaddat N, Dennis J, Zanti M, et al
    Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.
    Breast Cancer Res. 2024;26:189.
    >> Share

  395. CHOI HL, Jeong SM, Jeon KH, Kim B, et al
    Depression risk among breast cancer survivors: a nationwide cohort study in South Korea.
    Breast Cancer Res. 2024;26:188.
    >> Share

  396. GIRNIUS N, Henstridge AZ, Marks B, Yu JK, et al
    Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.
    Breast Cancer Res. 2024;26:187.
    >> Share

  397. CARUSO JA, Chen-Tanyolac C, Tlsty TD
    A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.
    Breast Cancer Res. 2024;26:184.
    >> Share

  398. PUPPO M, Croset M, Ceresa D, Valluru MK, et al
    Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.
    Breast Cancer Res. 2024;26:186.
    >> Share

  399. KOHLER KT, Kim J, Villadsen R, Ronnov-Jessen L, et al
    Oncogene activated human breast luminal progenitors contribute basally located myoepithelial cells.
    Breast Cancer Res. 2024;26:183.
    >> Share

  400. BAE SJ, Kim JH, Kim MJ, Kook Y, et al
    Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study.
    Breast Cancer Res. 2024;26:182.
    >> Share

  401. MITSIADES IR, Onozato M, Iafrate AJ, Hicks D, et al
    ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.
    Breast Cancer Res. 2024;26:185.
    >> Share

  402. GAO SY, Lin TC, Liu LC, Chen WL, et al
    Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI.
    Breast Cancer Res. 2024;26:181.
    >> Share

  403. HAN E, Choi HY, Kwon HJ, Chung YR, et al
    Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:180.
    >> Share

  404. TERRY MB, English DR, Freudenheim JL, Lauby-Secretan B, et al
    Alcohol cessation and breast cancer risk stratified by hormone receptor status.
    Breast Cancer Res. 2024;26:179.
    >> Share

  405. LEE DN, Li Y, Olsson LT, Hamilton AM, et al
    Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers.
    Breast Cancer Res. 2024;26:177.
    >> Share

  406. DEBELJAK M, Cho S, Downs BM, Considine M, et al
    Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
    Breast Cancer Res. 2024;26:178.
    >> Share

  407. COUNCELL KA, Polcari AM, Nordgren R, Skolarus TA, et al
    Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study.
    Breast Cancer Res. 2024;26:176.
    >> Share

  408. DE LA CRUZ P, McAdams J, Morales Aquino M, Fernandez AI, et al
    NF-kappaB associated markers of prognosis in early and metastatic triple negative breast cancer.
    Breast Cancer Res. 2024;26:175.
    >> Share

    November 2024
  409. JUNG J, Kim NH, Park J, Lim D, et al
    Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.
    Breast Cancer Res. 2024;26:174.
    >> Share

  410. LIU J, Sun W, Li N, Li H, et al
    Uncovering immune cell-associated genes in breast cancer: based on summary data-based Mendelian randomized analysis and colocalization study.
    Breast Cancer Res. 2024;26:172.
    >> Share

  411. MORGAN E, O'Neill C, Shah R, Langselius O, et al
    Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2024;26:171.
    >> Share

  412. SHAHROUZI P, Azimzade Y, Brankiewicz-Kopcinska W, Bhatia S, et al
    Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.
    Breast Cancer Res. 2024;26:170.
    >> Share

  413. GORANSSON S, Hernandez-Varas P, Hammarstrom M, Hellgren R, et al
    Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.
    Breast Cancer Res. 2024;26:163.
    >> Share

  414. CHERNOSKY NM, Tamagno I, Polak KL, Chan ER, et al
    Toll-Like receptor 3-mediated interferon-beta production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.
    Breast Cancer Res. 2024;26:167.
    >> Share

  415. TEHRANIFAR P, Lee Argov EJ, Athilat S, Liao Y, et al
    Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study.
    Breast Cancer Res. 2024;26:166.
    >> Share

  416. KRESOVICH JK, Guranich C, Houghton S, Qian J, et al
    Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.
    Breast Cancer Res. 2024;26:169.
    >> Share

  417. FOO J, Gentile F, Massah S, Morin H, et al
    Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2).
    Breast Cancer Res. 2024;26:168.
    >> Share

  418. KOOK Y, Lee YJ, Chu C, Jang JS, et al
    Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.
    Breast Cancer Res. 2024;26:164.
    >> Share

  419. GEHLING GM, Alfaqih M, Pruinelli L, Starkweather A, et al
    A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.
    Breast Cancer Res. 2024;26:165.
    >> Share

  420. BI K, Chen M, Zhao Q, Yang T, et al
    The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER + breast cancer but not ER- breast cancer.
    Breast Cancer Res. 2024;26:161.
    >> Share

  421. YOHANNES M, Desalegn Z, Bauer M, Stuckrath K, et al
    Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients.
    Breast Cancer Res. 2024;26:162.
    >> Share

  422. CHEN H, Liu Y, Zhao J, Jia X, et al
    Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study.
    Breast Cancer Res. 2024;26:160.
    >> Share

  423. MERCOEUR B, Fervers B, Coudon T, Noh H, et al
    Exposure to air pollutants and breast cancer risk: mediating effects of metabolic health biomarkers in a nested case-control study within the E3N-Generations cohort.
    Breast Cancer Res. 2024;26:159.
    >> Share

  424. WADA K, Kuboyama K, Abe SK, Rahman MS, et al
    Body mass index and breast cancer risk in premenopausal and postmenopausal East Asian women: a pooled analysis of 13 cohort studies.
    Breast Cancer Res. 2024;26:158.
    >> Share

  425. XIONG L, Tang X, Jiang X, Chen H, et al
    Automatic segmentation-based multi-modal radiomics analysis of US and MRI for predicting disease-free survival of breast cancer: a multicenter study.
    Breast Cancer Res. 2024;26:157.
    >> Share

  426. LEE C, Yip H, Li JJX, Ng J, et al
    Clinical values of nuclear morphometric analysis in fibroepithelial lesions.
    Breast Cancer Res. 2024;26:156.
    >> Share

  427. KOOK Y, Lee YJ, Chu C, Jang JS, et al
    Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis.
    Breast Cancer Res. 2024;26:154.
    >> Share

  428. ZUO X, Zhao X, Zhang X, Li Q, et al
    PTPN20 promotes metastasis through activating NF-kappaB signaling in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:155.
    >> Share

  429. MANOUCHEHRI JM, Datta J, Marcho LM, Reardon JJ, et al
    The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:153.
    >> Share

  430. LEE YJ, Noh WC, Gwark S, Kim HA, et al
    Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.
    Breast Cancer Res. 2024;26:152.
    >> Share

  431. BUSUND M, Ursin G, Lund E, Chen SLF, et al
    Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study.
    Breast Cancer Res. 2024;26:151.
    >> Share

  432. CHRISTENSEN MH, Vinter CA, Olesen TB, Petersen MH, et al
    Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study.
    Breast Cancer Res. 2024;26:150.
    >> Share

    October 2024
  433. PUTHANMADHOM NARAYANAN S, Wedn AM, Shah OS, Chen J, et al
    Transcriptomic analysis identifies enrichment of cAMP/PKA/CREB signaling in invasive lobular breast cancer.
    Breast Cancer Res. 2024;26:149.
    >> Share

  434. ZHAO F, Polley E, McClellan J, Howard F, et al
    Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.
    Breast Cancer Res. 2024;26:148.
    >> Share

  435. JIN S, Zheng Y, Li D, Liu X, et al
    Effect of genistein supplementation on microenvironment regulation of breast tumors in obese mice.
    Breast Cancer Res. 2024;26:147.
    >> Share

  436. WU W, Zhu J, Nihira NT, Togashi Y, et al
    Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B.
    Breast Cancer Res. 2024;26:146.
    >> Share

  437. DWYER S, Ruth J, Seidel HE, Raz AA, et al
    Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy.
    Breast Cancer Res. 2024;26:143.
    >> Share

  438. CHEN J, Kehm R, Yang W, Terry MB, et al
    Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns.
    Breast Cancer Res. 2024;26:145.
    >> Share

  439. PILEHVARI A, Kimmick G, You W, Bonilla G, et al
    Disparities in receipt of 1-(st) line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.
    Breast Cancer Res. 2024;26:144.
    >> Share

  440. LINDHOLM A, Abrahamsen ML, Buch-Larsen K, Marina D, et al
    Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study.
    Breast Cancer Res. 2024;26:142.
    >> Share

  441. WU HC, Lai Y, Liao Y, Deyssenroth M, et al
    Plasma metabolomics profiles and breast cancer risk.
    Breast Cancer Res. 2024;26:141.
    >> Share

  442. NADER-MARTA G, Singer C, Hlauschek D, DeMichele A, et al
    Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
    Breast Cancer Res. 2024;26:140.
    >> Share

    September 2024
  443. O'DRISCOLL J, Burton A, Maskarinec G, Perez-Gomez B, et al
    Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study.
    Breast Cancer Res. 2024;26:139.
    >> Share

  444. SINN BV, Sychra K, Untch M, Karn T, et al
    On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res. 2024;26:138.
    >> Share

  445. JIANG B, Bao L, He S, Chen X, et al
    Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.
    Breast Cancer Res. 2024;26:137.
    >> Share

  446. BORAKA O, Sartor H, Sturesdotter L, Hall P, et al
    WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer.
    Breast Cancer Res. 2024;26:136.
    >> Share

  447. ZHANG N, Wang Q, Lu Y, Wang F, et al
    The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5.
    Breast Cancer Res. 2024;26:135.
    >> Share

  448. OZANNE EM, Maves K, Tramontano AC, Lynch T, et al
    Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25).
    Breast Cancer Res. 2024;26:134.
    >> Share

  449. TARANTO P, de Brito Sales D, Maluf FC, Guendelmann RAK, et al
    Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy.
    Breast Cancer Res. 2024;26:133.
    >> Share

  450. OMAR M, Harrell JC, Tamimi R, Marchionni L, et al
    A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
    Breast Cancer Res. 2024;26:132.
    >> Share

  451. LIEN HC, Yu HC, Yu WH, Lin SF, et al
    Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma.
    Breast Cancer Res. 2024;26:130.
    >> Share

  452. PHUNG AT, Shah JR, Dong T, Reid T, et al
    CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.
    Breast Cancer Res. 2024;26:131.
    >> Share

  453. ZHANG Y, Zhong F, Liu L
    Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer.
    Breast Cancer Res. 2024;26:129.
    >> Share

  454. XUE X, Guo L, Guo C, Xu L, et al
    Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China.
    Breast Cancer Res. 2024;26:128.
    >> Share

  455. STRAND SH, Houlahan KE, Branch V, Lynch T, et al
    Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome.
    Breast Cancer Res. 2024;26:127.
    >> Share

    August 2024
  456. INGEBRIKTSEN LM, Humlevik ROC, Svanoe AA, Saele AKM, et al
    Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.
    Breast Cancer Res. 2024;26:126.
    >> Share

  457. VAN BOCKSTAL MR, Wesseling J, Lips EH, Smidt M, et al
    Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Breast Cancer Res. 2024;26:125.
    >> Share

  458. VALIERIS R, Martins L, Defelicibus A, Bueno AP, et al
    Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides.
    Breast Cancer Res. 2024;26:124.
    >> Share

  459. SHARMA A, Lovgren SK, Eriksson KL, Wang Y, et al
    Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images.
    Breast Cancer Res. 2024;26:123.
    >> Share

  460. MORAGAS N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, et al
    The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.
    Breast Cancer Res. 2024;26:122.
    >> Share

  461. ZHAO Y, Song Y, Li X, Guo A, et al
    Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study.
    Breast Cancer Res. 2024;26:121.
    >> Share

    July 2024
  462. LEE J, Park S, Bae SJ, Ji J, et al
    Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy.
    Breast Cancer Res. 2024;26:120.
    >> Share

  463. HAO J, Jin R, Yi Y, Jiang X, et al
    Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer.
    Breast Cancer Res. 2024;26:119.
    >> Share

  464. KADAMKULAM SYRIAC A, Nandu NS, Clark A, Tavallai M, et al
    Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes.
    Breast Cancer Res. 2024;26:118.
    >> Share

  465. HUANG Y, Chen C, Liu Y, Tan B, et al
    Downregulation of tRF-Cys-GCA-029 by hyperglycemia promotes tumorigenesis and glycolysis of diabetic breast cancer through upregulating PRKCG translation.
    Breast Cancer Res. 2024;26:117.
    >> Share

  466. MBURU W, Guo C, Tian Y, Koka H, et al
    Associations between quantitative measures of mammographic density and terminal ductal lobular unit involution in Chinese breast cancer patients.
    Breast Cancer Res. 2024;26:116.
    >> Share

  467. KADER T, Provenzano E, Jayawardana MW, Hendry S, et al
    Stromal lymphocytes are associated with upgrade of B3 breast lesions.
    Breast Cancer Res. 2024;26:115.
    >> Share

  468. GAO H, Wei L, Indulkar S, Nguyen TTL, et al
    Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.
    Breast Cancer Res. 2024;26:111.
    >> Share

  469. YANG X, Liu Q, Guo Z, Yang X, et al
    Promoter profiles in plasma CfDNA exhibits a potential utility of predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2024;26:112.
    >> Share

  470. SUBRAMANYAN LV, Rasheed SAK, Wang L, Ghosh S, et al
    GNA13 suppresses proliferation of ER+ breast cancer cells via ERalpha dependent upregulation of the MYC oncogene.
    Breast Cancer Res. 2024;26:113.
    >> Share

  471. XIAO D, Zhang M, Qu Y, Su X, et al
    Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target.
    Breast Cancer Res. 2024;26:110.
    >> Share

  472. HENG YJ, Baker GM, Fein-Zachary VJ, Guzman-Arocho YD, et al
    Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.
    Breast Cancer Res. 2024;26:109.
    >> Share

  473. WANG C, Nagayach A, Patel H, Dao L, et al
    Utilizing human cerebral organoids to model breast cancer brain metastasis in culture.
    Breast Cancer Res. 2024;26:108.
    >> Share

    June 2024
  474. SINEVICI N, Edmonds CE, Dontchos BN, Wang G, et al
    A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.
    Breast Cancer Res. 2024;26:107.
    >> Share

  475. FIFIELD BA, Vusich J, Haberfellner E, Andrechek ER, et al
    Atypical cell cycle regulation promotes mammary stem cell expansion during mammary development and tumourigenesis.
    Breast Cancer Res. 2024;26:106.
    >> Share

  476. WANG D, Yang S, Lyu M, Xu L, et al
    Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway.
    Breast Cancer Res. 2024;26:105.
    >> Share

  477. LU Y, Houson HA, Gallegos CA, Mascioni A, et al
    Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Breast Cancer Res. 2024;26:104.
    >> Share

  478. FANG Y, Wang Y, Ma H, Guo Y, et al
    TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription.
    Breast Cancer Res. 2024;26:103.
    >> Share

  479. HARRIS AR, Wang T, Heng YJ, Baker GM, et al
    Association of early menarche with breast tumor molecular features and recurrence.
    Breast Cancer Res. 2024;26:102.
    >> Share

  480. BHIMANI J, O'Connell K, Ergas IJ, Foley M, et al
    Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019.
    Breast Cancer Res. 2024;26:101.
    >> Share

  481. ZHANG Y, Chen F, Balic M, Creighton CJ, et al
    An essential gene signature of breast cancer metastasis reveals targetable pathways.
    Breast Cancer Res. 2024;26:98.
    >> Share

  482. LIEN HC, Lo C, Lee YH, Lin PH, et al
    In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
    Breast Cancer Res. 2024;26:100.
    >> Share

  483. DU J, Liu X, Sun J, Wu Q, et al
    Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:99.
    >> Share

  484. LEON-FERRE RA, Whitaker KR, Suman VJ, Hoskin T, et al
    Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
    Breast Cancer Res. 2024;26:97.
    >> Share

  485. COLEMAN MF, Cotul EK, Pfeil AJ, Devericks EN, et al
    Hypoxia-mediated repression of pyruvate carboxylase drives immunosuppression.
    Breast Cancer Res. 2024;26:96.
    >> Share

  486. LAINE M, Greene ME, Kurleto JD, Bozek G, et al
    Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
    Breast Cancer Res. 2024;26:95.
    >> Share

  487. ZHANG X, An K, Ge X, Sun Y, et al
    NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation.
    Breast Cancer Res. 2024;26:94.
    >> Share

  488. DUIVON M, Lequesne J, Di Meglio A, Pradon C, et al
    Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
    Breast Cancer Res. 2024;26:93.
    >> Share

  489. JIN X, Yang S, Lu X, Chen X, et al
    Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
    Breast Cancer Res. 2024;26:92.
    >> Share

  490. FARALDO MM, Romagnoli M, Wallon L, Dubus P, et al
    Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
    Breast Cancer Res. 2024;26:91.
    >> Share

  491. MORLA-BARCELO PM, Laguna-Macarrilla D, Cordoba O, Matheu G, et al
    Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.
    Breast Cancer Res. 2024;26:89.
    >> Share

  492. BOISSIN C, Wang Y, Sharma A, Weitz P, et al
    Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images.
    Breast Cancer Res. 2024;26:90.
    >> Share

    May 2024
  493. JOHN EM, Koo J, Phipps AI, Longacre TA, et al
    Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    Breast Cancer Res. 2024;26:88.
    >> Share

  494. GLOTZBACH A, Rohlf K, Gonscharow A, Luke S, et al
    EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.
    Breast Cancer Res. 2024;26:87.
    >> Share

  495. RAGHURAM N, Temel EI, Kawamata T, Kozma KJ, et al
    Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
    Breast Cancer Res. 2024;26:86.
    >> Share

  496. JONES LI, Marshall A, Geach R, Elangovan P, et al
    Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using a
    Breast Cancer Res. 2024;26:85.
    >> Share

  497. KUKLINSKI D, Blum M, Subelack J, Geissler A, et al
    Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival.
    Breast Cancer Res. 2024;26:84.
    >> Share

  498. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:83.
    >> Share

  499. LIU C, Sun M, Arefan D, Zuley M, et al
    Deep learning of mammogram images to reduce unnecessary breast biopsies: a preliminary study.
    Breast Cancer Res. 2024;26:82.
    >> Share

  500. VAN CAUWENBERGE J, Van Baelen K, Maetens M, Geukens T, et al
    Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
    Breast Cancer Res. 2024;26:81.
    >> Share

  501. MAO H, Jin M, Xie L, Mao N, et al
    Infrared laser moxibustion for cancer-related fatigue in breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2024;26:80.
    >> Share

  502. NELSON A, McMullen N, Gebremeskel S, De Antueno R, et al
    Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Breast Cancer Res. 2024;26:78.
    >> Share

  503. MARIAPUN S, Ho WK, Eriksson M, Mohd Taib NA, et al
    Association of area- and volumetric-mammographic density and breast cancer risk in women of Asian descent: a case control study.
    Breast Cancer Res. 2024;26:79.
    >> Share

  504. ZHANG X, Teng X, Zhang J, Lai Q, et al
    Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
    Breast Cancer Res. 2024;26:77.
    >> Share

  505. RAJ-KUMAR PK, Lin X, Liu T, Sturtz LA, et al
    Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.
    Breast Cancer Res. 2024;26:76.
    >> Share

  506. OMILIAN AR, Cannioto R, Mendicino L, Stein L, et al
    CD163(+) macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study.
    Breast Cancer Res. 2024;26:75.
    >> Share

    April 2024
  507. SMITH RE, Sprague BL, Henderson LM, Kerlikowske K, et al
    Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
    Breast Cancer Res. 2024;26:73.
    >> Share

  508. CHAUDHARY P, Yadav K, Lee HJ, Kang KW, et al
    siRNA treatment targeting integrin alpha11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Breast Cancer Res. 2024;26:72.
    >> Share

  509. HE L, Qin Y, Hu Q, Liu Z, et al
    Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging.
    Breast Cancer Res. 2024;26:71.
    >> Share

  510. LIAO R, Chen X, Cao Q, Bai L, et al
    AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
    Breast Cancer Res. 2024;26:70.
    >> Share

  511. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:69.
    >> Share

  512. PAN JW, Ragu M, Chan WQ, Hasan SN, et al
    Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
    Breast Cancer Res. 2024;26:67.
    >> Share

  513. KWON MR, Chang Y, Ham SY, Cho Y, et al
    Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection.
    Breast Cancer Res. 2024;26:68.
    >> Share

  514. BAE SJ, Chun JW, Lee SB, Ryu JM, et al
    Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.
    Breast Cancer Res. 2024;26:66.
    >> Share


  515. Meeting Abstracts from the British Society of Breast Radiology annual scientific meeting 2023.
    Breast Cancer Res. 2024;26.
    >> Share

  516. ZHANG N, Huang Y, Wang G, Xiang Y, et al
    Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
    Breast Cancer Res. 2024;26:64.
    >> Share

  517. BAE SJ, Kook Y, Jang JS, Baek SH, et al
    Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
    Breast Cancer Res. 2024;26:65.
    >> Share

  518. SALEMBIER R, De Haes C, Bellemans J, Demeyere K, et al
    Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
    Breast Cancer Res. 2024;26:63.
    >> Share

  519. ZHANG W, Song X, Jin Z, Zhang Y, et al
    U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
    Breast Cancer Res. 2024;26:60.
    >> Share

  520. KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
    Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
    Breast Cancer Res. 2024;26:61.
    >> Share

  521. WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
    Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Breast Cancer Res. 2024;26:59.
    >> Share

  522. BASHARI MH, Fan F, Vallet S, Sattler M, et al
    Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Breast Cancer Res. 2024;26:58.
    >> Share

    March 2024
  523. OLIPHANT MUJ, Akshinthala D, Muthuswamy SK
    Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
    Breast Cancer Res. 2024;26:56.
    >> Share

  524. CHI F, Griffiths JI, Nath A, Bild AH, et al
    Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Breast Cancer Res. 2024;26:54.
    >> Share

  525. SAFAEI S, Fadaee M, Farzam OR, Yari A, et al
    Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
    Breast Cancer Res. 2024;26:57.
    >> Share

  526. WALLACE G, Kundalia R, Vallebuona E, Cao B, et al
    Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Breast Cancer Res. 2024;26:55.
    >> Share

  527. MULLOOLY M, Fan S, Pfeiffer RM, Bowles EA, et al
    Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease.
    Breast Cancer Res. 2024;26:52.
    >> Share

  528. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:53.
    >> Share

  529. HAMILTON AM, Walens A, Van Alsten SC, Olsson LT, et al
    BIRC5 expression by race, age and clinical factors in breast cancer patients.
    Breast Cancer Res. 2024;26:50.
    >> Share

  530. MCCLELLAN JC, Li JL, Gao G, Huo D, et al
    Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
    Breast Cancer Res. 2024;26:51.
    >> Share

  531. LEE J, Lee G, Park HS, Jeong BK, et al
    Factors associated with engraftment success of patient-derived xenografts of breast cancer.
    Breast Cancer Res. 2024;26:49.
    >> Share

  532. HU R, Cao Y, Wang Y, Zhao T, et al
    TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via beta1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Breast Cancer Res. 2024;26:48.
    >> Share

  533. GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
    Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
    Breast Cancer Res. 2024;26:47.
    >> Share

  534. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
    Breast Cancer Res. 2024;26:46.
    >> Share

  535. PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
    Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
    Breast Cancer Res. 2024;26:45.
    >> Share

  536. JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
    The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
    Breast Cancer Res. 2024;26:42.
    >> Share

  537. CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
    Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
    Breast Cancer Res. 2024;26:43.
    >> Share

  538. BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
    HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Breast Cancer Res. 2024;26:41.
    >> Share

  539. LI J, Liang Y, Zhou S, Chen J, et al
    UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Breast Cancer Res. 2024;26:44.
    >> Share

  540. ZHAO L, Xing Y, Liu C, Ma S, et al
    Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
    Breast Cancer Res. 2024;26:40.
    >> Share

  541. CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
    Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Breast Cancer Res. 2024;26:38.
    >> Share

  542. HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
    How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
    Breast Cancer Res. 2024;26:39.
    >> Share

  543. JIANG X, Wang Y, Guo L, Wang Y, et al
    The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
    Breast Cancer Res. 2024;26:37.
    >> Share

  544. RODON J, Demanse D, Rugo HS, Burris HA, et al
    A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Breast Cancer Res. 2024;26:36.
    >> Share

  545. SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Breast Cancer Res. 2024;26:35.
    >> Share

    February 2024
  546. SONG T, Zhang H, Zhao Q, Hu Z, et al
    Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Breast Cancer Res. 2024;26:33.
    >> Share

  547. EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
    PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
    Breast Cancer Res. 2024;26:34.
    >> Share

  548. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
    Breast Cancer Res. 2024;26:32.
    >> Share

  549. JUNG M, Song SG, Cho SI, Shin S, et al
    Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Breast Cancer Res. 2024;26:31.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016